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THESIS ABSTRACT 
Title: 
To assess prevalence of fatigue and other extra-pulmonary manifestations in patients with 
Sarcoidosis 
Department:  Pulmonary Medicine 
Name of candidate: Dr Immanuel Subash G 
Degree and Subject:  MD Pulmonary medicine 
Name of the Guide: Dr D J Christopher 
 
Objectives: 
2 objectives of the study: 
Primary objective:  To assess the prevalence of fatigue with the help of FAS ( Fatigue 
assessment scale)in all patents with Histo-pathologically proven sarcoidosis, both old and 
new, treatment naïve and on treatment,  in the department of Pulmonary Medicine. 
Secondary objective:  Secondary objective of the study was to observe and present the 
prevalence of other extra-pulmonary manifestations in the same cohort. 
Methods: 
We included all patients in our department with the diagnosis of Sarcoidosis, which was 
proven histo-pathologically. Both newly diagnosed and patients who were on treatment 
were included. They were asked to fill in a Quality of life questionnaire – FAS (Fatigue 
assessment scale), which has been validated for use in patients with sarcoidosis to assess 
fatigue.  A score of more than 21 was considered to be significant for fatigue. For assessing 
other extra-pulmonary manifestations basic screening tests which were done as part of 
routine work up was used, Ophthalmological and Dermatological screening was done for all 
of them. 
 
Results: 
We included 75 patients in our study. We found fatigue as a symptom with the help of FAS 
more than 21 in 73.3% of patients. In newly diagnosed patients prevalence was 85.7% 
compared to old patients in who it was 66%.  Patients on steroids had 9% higher risk of 
having fatigue, but statistically it was not found to be significant (odd’s ratio; 0.98, p value; 
0.752).  There was no significant difference statistically in age or female sex – odd’s ratio of 
0.99 and 1.09 respectively.  Assessing other extra-pulmonary manifestations we found 
highest prevalence in Eye and Skin with 26% and 20% respectively.  Other organs involved in 
decreasing order of prevalence were Liver (13%), Bone/Joint/Muscle (10.6%), Spleen (9.3%), 
Calcium/Kidney (6.6%), Brain (4%), ENT (4%), Heart (1.3%), and Parotid gland (1.3%). 
INTRODUCTION: 
 
Sarcoidosis is a multi-system disease of unknown aetiology which is typically characterised 
by presence of non-caseating granulomas in the organs which are involved.  Sarcoidosis 
term comes from the Greek words "Sark" and "oid," meaning flesh-like.   Sarcoidosis 
typically affects the  lungs in 90% of patients(1), presenting as mediastinal adenopathy ,  
Pulmonary infiltrates, interstitial lung disease, it is also commonly known to involve other 
organs notably skin and eyes.  Sarcoidosis can involve any organ like liver, spleen, brain, 
heart or any other organ.  Sarcoidosis may simultaneously affect 2 or more organs.  It is 
important to identify all the organs involved at the time of diagnosis for treatment and 
follow up of the patient.   
Sarcoidosis is a diagnosis made on the basis of a multi-disciplinary approach including an apt 
clinical picture with correlating radiological findings and proven histo-pathologically from 
the organ involved.  Clinically patients with Sarcoidosis present with symptoms in 
concordance with the organ involved.  The most common organ being involved with 
Sarcoidosis is the lung they present with symptoms of cough, breathlessness and chest pain.  
They may also present with other symptoms like weight loss, loss of appetite, fatigue.  In 
few patients Sarcoidosis may be identified on a Chest x-ray done for some other reason.  
Patients with Sarcoidosis have extra-thoracic involvement in up to 30% of cases and may 
present with organ specific symptoms before pulmonary manifestations.   
 
 
Radiologically Sarcodosis commonly affects the hilar and mediastinal lymphadenopathy with 
or without parenchymal infiltrates.  Radiological classification at the time of diagnosis has 
been found to be important in follow up of patients with sarcoidosis.  Chest x-ray might be 
the clue to suspicion in a patient.  Sarcoidosis must always be considered as a differential in 
a patient presenting with cough, breathlessness and other symptoms like fatigue. 
Following is the most accepted classification world-side for sarcoidosis which can be used 
with ease in a primary health care hospital. 
 
Radiological classification of Sarcoidosis: 
A) Stage 0: Normal Chest radiograph 
B) Stage 1: Bilateral hilar adenopathy ( Indicated by arrows) 
C) Stage 2: Bilateral hilar adeopathy with parenchymal infiltrates 
D) Stage 3: Evidence of reticular opacities with shrinking hilar lymph nodes 
E) Stage 4: Evidence of reticular opacities with fibrosis and volume loss 
 
 
 
 
HRCT done to characterise the pattern of involvement may show any of the following: 
●Hilar and mediastinal lymphadenopathy 
●Beaded or irregular thickening of the bronchovascular bundles 
●Nodules along bronchi, vessels, and subpleural regions 
●Bronchial wall thickening 
●Ground glass opacification 
●Parenchymal masses or nodular consolidation, occasionally with cavitation 
●Parenchymal bands 
●Cysts 
●Fibrosis with distortion of the lung architecture and traction bronchiectasis 
Pulmonary function testing commonly shows restrictive lung defect, in 20% of cases it may 
present with an obstructive defect or a mixed defect(2) 
 
Sarcoidosis is typically characterised by presence of non caseating granulomatous 
inflammation demonstrated from a tissue from the organ involved(3), it is important to 
exclude other common causes of granulomatous inflammation which can be infectious like 
tuberculosis or fungal infections like histoplasmosis.  Non-infectious causes of  
granulomatous inflammation other than Sarcoidosis are Wegener’s granulomatosis, 
Hypersensitivity pneumonitis, Aspiration pneumonia(4).   
 
Sarcoidosis is not as rare as it is thought to be (2), looking at studies which have been 
mentioned in the review of literature we found that Sarcoidosis is known to cause 
significant fatigue affecting quality of life of patients diagnosed with the same.  
 The aim of our study was to calculate the prevalence of fatigue in patients who are 
diagnosed with pulmonary sarcoidosis. We also looked to observe and present the 
prevalence of other extra-pulmonary manifestations in the same cohort of patients.  
 
Treatment of sarcoidosis: 
Not all patients with sarcoidosis will require treatment.  Therapy is indicated in patients in 
pulmonary sarcoidosis only in the following circumstances: 
Bothersome symptoms – breathlessness, cough 
Worsening radiological features 
Rapid worsening lf lung function as indicated by Pulmonary function testing 
 It is important to identify at the time of diagnosis and only treat patients who require 
treatment as per guidelines. 
Goals of treatment in a patient with sarcoidosis are(5): 
Control and prevent organ damage 
Relief from symptoms 
Improve quality of life 
A multi- disciplinary approach is recommended for diagnosis before intitiation of treatment.  
Pulmonologist, radiologist and pathologist should agree with the diagnosis of sarcoidosis 
before starting a patient on treatment. 
Patients with extra-pulmonary manifestations also demand management by the concerned 
specialist rather than the pulmonologist for the concerned organ involvement. 
 
Treatment options: 
To treat sarcoidosis, pharmacotherapies which have been tried are the following(5): 
 
 Corticosteroids 
 Hydroxychloroquine 
 Methotrexate 
 Azathioprine 
 Leflunomide 
 Mycophenolate 
 Infliximab 
 Adalimumab 
 
Corticosteroids have been the mainstay of treatment.  They act by their anti-inflammatory 
property by their effect on the granulomas. 
 
Corticosteroids have been found to be useful in sarcoidosis, but adverse effects should 
always be kept in mind before starting a patient on sarcoidosis.  Patient should be taken into 
confidence before inception of therapy. He/she should understand all the side effects 
including weight gain, decreased bone mineral density, increased blood sugars and 
increased blood pressures after initiating therapy.  They should be advised to be screened 
regularly for these effects of steroids.  Other agents mentioned above should be used only if 
there is failure of treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Epidemiology: 
 
Sarcoidosis is one of the rare  diseases.  Here is the known epidemiology of Sarcoidosis 
worldwide and in India. 
 
World-wide: 
 
Epidemiology of sarcoidosis as per various studies range from 5- 40 per 1,00,00 people.(6) 
with variation among Europeans, Americans, Japanese and Afro-Americans.  In some areas it 
can be as high as 640 per 1,00,00 people(7). 
Prevalence of sarcoidosis has been found to be slightly more in females compared to 
males(8) 
India: 
 
In India the prevalence of Sarcodiosis varies from 10-150 according to the available data.(9) 
(10),  
 
 
 
AIM AND OBJECTIVES: 
 
Aim –  
 
Assessment of fatigue and other extra-pulmonary manifestations in patients  
diagnosed with Pulmonary Sarcoidosis  
 
Objectives –  
 
Primary:  
 
Prevalence of Fatigue in all patients diagnosed with Sarcoidosis in the department of Pulmonary 
Medicine.  
 Secondary: 
 
 Assess the extra-pulmonary manifestations of Sarcoidosis in the same Cohort of patients 
  
  
Review of literature: 
 
Sarcoidosis is a disease of unknown aetiology; it is known to produce non caseating 
granulomas in various organs. It is known to affect lung primarily, but can involve any organ 
in the body.  Prevalence of sarcoidosis as mentioned in the epidemiology section of this 
study ranges from 0.03 to 640 per 1,00,000 depending on the sec, age and race(5). Common 
symptoms with which patients with Sarcoidosis present are that of pulmonary involvement 
with cough, breathlessness, but other nonspecific symptoms of sarcoidosis are fatigue, 
generalised weakness and loss of appetite and weight which don’t directly correspond to 
the physical evidence available of the disease(11).   
 
 
 
 
 
 
  
 
What is Fatigue?? 
 
Fatigue in common terms can be used for lethargy, excessive tiredness, and weakness.  
Fatigue is not only seen in many acute and chronic medical illnesses, but can also be seen in 
normal individuals in day to day life.  It may hence be said that fatigue can be physiological, 
psychological or behavioural phenomena(12).  Fatigue is one of the common symptoms 
patients might come out with once asked for, it rarely is the presenting symptom.  Diseases 
other that Sarcoidosis which can cause fatigue may be related to the following: 
A) Life-style habits: excessive alcohol intake, excessive physical activity, inactivity, lack 
of sleep, medications such as antihistamines,  cough suppressants and unhealthy 
eating habits 
B) Psychological conditions: Anxiety, Depression, Grief and stress. 
C) Medical conditions: Sarcoidosis, Hypothyroidism, Hyperthyroidism, Type 1 Diabetes 
Mellitus, Type 2 Diabetes Mellitus, Malignancy, Chronic fatigue syndrome, Chronic 
obstructive Pulmonary disease, Acute liver failure, Anaemia, Obesity, Obstructive 
sleep apnoea,  Chronic kidney disease and medications like anti-depressants and 
anti-hypertensive. 
 
 
 
  
 
Is Fatigue common in Sarcoidosis: 
 
Fatigue is found to be very common among patients with Sarcoidosis.  Fatigue is one of the 
most important symptoms affecting quality of life in patients with Sarcoidosis(13). Fatigue is 
defined as extreme tiredness due to physical, mental stress or illness.  Fatigue is a symptom 
which is commonly neglected by patients and physicians.  It has been seen that significant 
fatigue directly affects the quality of life of patients(14)(15) (16)(17)(18), hence affecting 
their socio-economic status.  Fatigue is one of the most important extra-pulmonary 
manifestations of Sarcoidosis which is most often ignored in a clinical setting. 
Prevalence of fatigue in Sarcoidosis: 
 
Fatigue in Sarcoidosis is found to be higher compared to normal controls(19)(17).  Fatigue 
was studied in many studies to identify the prevalence and burden in patients with 
Sarcoidosis. Different studies show variable prevalence ranging from 30 – 90%(20)(21) 
Sarcoidosis has been seen to present with fatigue in variable prevalence which may be 
because of the race as seen in a study done to compare the prevalence of fatigue in 
American and Dutch patients and found a higher prevalence of fatigue in American 
patients(22).    
 
Sarcoidosis is thought to be an individual process and continues to progress irrespective of 
treatment of  Sarcoidosis with drugs(23).  There are only few Indian studies looking at the 
prevalence of fatigue which have the prevalence to vary from 30-70%, there are few reports 
from other places in India which have varied prevalence from 61.2-150 per 1,00,00 
patients(10).  Such high prevalence of Fatigue warrants urgent medical attention as it is seen 
as one of the most common extra-pulmonary manifestation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
How to objectively measure Fatigue in patients 
with Sarcoidosis?? 
 
We looked at various literatures to identify tools which have been used to assess fatigue in 
patients with Sarcoidosis.  
Following are the tools which were identified: 
 WHOQOL-100 ( Mean 100 item World Health Organisation Quality of life 
questionnaire)(15): 
 Questionnaire comprises of 100 item dealing with physical health quality, social, spiritual 
and level of independence graded on a 5 point likert scale from 1( Never) to 5 ( Always), it 
takes 15-20 minutes and is considered to be good in patients with Sarcoidosis. 
 
 CRQ (Chronic Respiratory disease questionnaire)(24):  
It consists of 20 items taking 20-30 minutes to fill, not considered to be appropriate for 
Sarcoidosis, but has been validated in interstitial lung disease 
 
 SF-36 (36 item Short form Health survey)(24):  
It is another health survey questionnaire which comprises of 36 items, takes about 10 
minutes to complete and is considered to be good in assessing fatigue in patients with 
Sarcoidosis. 
 SGRQ (St George’s Respiratory Questionnaire)(15): Comprises of 76 items and 
consumes around 10-15 minutes. It is considered to be good for Sarcoidosis patients. 
SHQ (Sarcoidosis Health Questionnaire): It is the only disease specific questionnaire 
comprising 29 items, takes about 10 minutes and is considered to be good in determining 
fatigue objectively. 
 
 SIP (Sickness Impact Profile): 
 It comprises of 136 items and takes about 20-30 minutes and is credibility in Sarcoidosis is 
unknown 
 
 DAL (Daily activity list) (25):  
Deals with usual activities, consists of 11 items and is not found to be the best in Sarcoidosis 
but has been used in studies to assess Fatigue and health related quality of life. 
 
 BFS (Borg Fatigue Score):  
It is a rating scale for fatigue, similar to the Borg dyspnoea scale which is used. It ranges 
from 0 which means no fatigue at all to 10 which is maximum fatigue. It has neither been 
found to be reliable nor specific for fatigue in Sarcoidosis patients(26) 
 
 
  CIS (Checklist individual strength):  
A 20 item questionnaire dealing with severity of fatigue, concentration problems, decreased 
motivation and decreased physical activity(27)(28)(28)(28) It has been used in a study 
dealing with Sarcoidosis remission patients and fatigue(28), but has not been validated to be 
used for assessment.  
 
 
 BDI ( Beck depression inventory): 
 It is a 21 question multiple choice self-report inventory which has been used in some 
studies for measuring fatigue(29) , but is found to be more useful in assessing depression in 
chronic diseases 
 
 FACIT-F (Functional assessment of chronic illness therapy - Fatigue):  
This score uses 13 items dealing with fatigue for the last 7 days. It has been used in studies 
to assess improvement in fatigue after treatment(30)(31). 
 
 
 
 
 Multi-dimensional fatigue inventory:  
It is a 20 item measure of fatigue covering general fatigue, mental fatigue, physical fatigue, 
reduced activity and motivation(32). It has been used in patients with Sarcoidosis as 
well(33)(34) 
 
 FAS ( Fatigue assessment scale):  
Most commonly used and validated questionnaire to assess fatigue in patients with 
Sarcoidosis is called as the Fatigue Assessment scale.(16)(29)(13)(33)(35)(30)(31)(36)(14).  
Since FAS has been validated for use in patients with Sarcoidosis, we used FAS in our study; 
it consists of 10 questions with a 5 point likert scale from never to always.  
 
 
 
 
 
 
 
 
 
FATIGUE ASSESSMENT SCALE 
 
 
 Why is FAS better than other Quality of life questionnaires? 
 
FAS has 10 simple questions which can be answered in less than 15 minutes.  It is found to 
be the most reliable and valid score which can be used for assessing fatigue in Sarcoidosis 
patients(13).  
 
Reliability of FAS in Sarcoidosis is proven by the following reasons: 
 Test - retest reliability is found to be good – 0.89, which is better than all the other 
scales mentioned above(29)(37) 
 FAS’ sensitivity to change is very good(29), hence it can be used in studies which deal 
with treatment of fatigue to measure objectively if significant change in fatigue is 
seen. 
 Cronbach’s alpha of FAS is also found to be good(38)(29) 
With the above mentioned reasons, it can safely be said that FAS has high internal 
consistency in measuring fatigue. 
 
Validity of FAS in sarcoidosis patients: 
 Construct validity of FAS is good as it has questions pertaining to physical and mental 
health with 8 questions having no gender bias(29)(39)(33). 
 Construct validity of FAS shows one underlying factor(38)(29). 
 MCID of FAS which is a four point change is also found to be valid(40), this will be 
useful both in following up Sarcoidosis patients and in clinical trials. 
 Discriminant validity of FAS is good and it has no floor or ceiling effects(38) 
Therefore, Fatigue assessment scale is the most reliable and valid score to assess fatigue in 
patients in Sarcoidosis in both clinical trials like ours and in outdoor settings as well. A score 
of 22 or more in Fatigue is considered to be significant fatigue(41) (42) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Causes of fatigue in sarcoidosis: 
 
Fatigue is common in Sarcoidosis as mentioned in the previous studies. Attempts to find the 
aetiology of fatigue in Sarcoidosis patients have been done. They found that the cause of 
fatigue is multifactorial(23)(13). Following are the causes identified for factors causing 
fatigue in Sarcodosis patients. 
Increased inflammation and metabolic dysfunction 
Increased inflammation results in granuloma formation and release of cytokines in 
Sarcoidosis which may lead to fatigue(13).  TNF Alpha which is also called as cachectin and 
Interleukin 1 and 6 levels are found to be high (21) which contributes to fatigue.(43) 
Myopathy – due to inflammation and/or drugs used to treat Sarcoidosis like steroids can 
cause myopathy(44)(16)(13). It can be part of the disease as an extra-pulmonary 
manifestation with muscle weakness(15). They can have either an acute polymyositis or a 
chronic myopathy, Chronic myopathy is more commonly associated with fatigue(45) 
Pain – Arthralgia is one of the extra-pulmonary manifestations in Sarcoidosis and can lead to 
fatigue.  Pain as part of the disease or due to neurological manifestations may present with 
fatigue(46) 
Altered sleep patterns and/or associated sleep disorders are commonly seen in patients 
with Sarcoidosis and can induce fatigue (15).  Sleep disorders like sleep apnoea, restless leg 
syndrome(47) have been found to more common in Sarcoidosis patients(48).  A study states 
that patients with Sarcoidosis have 6-8 times increased prevalence of sleep disorder 
compared to normal population(49) 
Psychological factors – significant number of patients with Sarcoidosis are seen to have 
anxiety and depression which mainly manifest as fatigue.  These psychological factors seem 
to play a very crucial role in causing fatigue(50).   Emotional stability in a study by 
Magnusson et all has been found to be the most important predictor of fatigue(51)(52) 
Involvement of the Central nervous system can be seen in Sarcoidosis patients and fatigue is 
found to be more in them compared to others  
Small fibre neuropathy – SFN is another common cause of fatigue and FAS scores are found 
to be higher in patients with SFN compared to non-Small fibre neuropathy Sarcoidosis 
patients(23)(46). It is a difficult condition to diagnose, but can be of use as TNF Alpha levels 
are found to higher in them and targeted therapy with Anti TNF Alpha drugs and immune 
globulins can be used(43)(50). 
Few studies have shown patients with Sarcodosis to have a lower PiMax compared to 
normal individuals which may affect them and lead to fatigue(53) 
It can thus be concluded that the exact cause of fatigue in patients with Sarcoidosis cannot 
be labelled to a single factor; multifactorial causation theory is the most accepted world-
wide explanation for cause of fatigue in Sarcoidosis. 
 
 
 
  
Types of Fatigue in Sarcoidosis: 
 
Fatigue in Sarcoidosis has been classified into many types.  Following are the available 
classification of fatigue: 
Early morning fatigue, Intermittent fatigue and after noon fatigue. This classification is not a 
validated classification(54) 
As study comparing the previous classification found the following results to be more valid 
for fatigue in Sarcoidosis 
Mild fatigue: Patients with no or mild complaints of fatigue 
Intermittent fatigue: Variable symptom of fatigue throughout the day 
All day fatigue: Feeling fatigued for the whole 
Above classification was approved by Kleijn et all and they advised psycho-social counselling 
for patients in the all-day fatigue group would be helpful as part of treatment(50). 
Post Sarcoidosis chronic fatigue syndrome: This syndrome has been described in patients 
with Sarcoidosis after they are treated. They present with myalgia, malaise and depression 
 
 
 
 
Treatment of fatigue in Sarcoidosis: 
 
Fatigue is one of the most common presenting symptom which may be ignored in a clinical 
setting may lead to poor quality of life. This may affect the holistic care which a physician 
would like to offer to his/her patients with Sarcoidosis. Trials have been done with 
neurostimulants for the treatment of fatigue in Sarcoidosis. Following are the drugs which 
have been studied in Sarcoidosis patients to treat fatigue(30)(31)(53). 
Methylphenidate/Dextro – Methylphenidate: In a cross over trial it was found that giving 
this drug improved fatigue with a MCID in FAS being 4.5.  It was given for 4 weeks to obtain 
the MCID of 4.5(40)(31). 
Armodafinil:  Armodafinil is the r isomer of modafinil, both of which have been used to treat 
excessive somnolence. A cross-over study demonstrated improvement in fatigue in patients 
with sarcoidosis (30). 
Anti TNF Alpha drugs: Anti TNF Alpha drugs like Infliximab and adalimumab have been 
studied in treating fatigue in Sarcoidosis with the hypothesis of reducing inflammation and 
reducing fatigue(37)(55) 
Methylphenidate, D-Methylphenidate and Armodafinil are grouped together as 
neurostimulants. They are not to be given at the diagnosis of fatigue in Sarcoidosis. First 
step to treat fatigue in Sarcoidosis is by treating the cause i.e. by treating Sarcoidosis(56) . In 
addition to drugs cognitive behavioural therapy and rehabilitation programmes also help to 
reduce fatigue in patients with Sarcoidosis. Following is the most appropriate clinical 
approach which is to followed to treat patients with fatigue as per clinical trials 
  
Maximising therapy for Sarcoidosis is the first step in managing fatigue, followed by treating 
co-existing disease like hypothyroidism, Diabetes mellitus and treating them appropriately.  
Evaluation of sleep apnoea with a polysomnography with or without depression needs to be 
identified and treated accordingly.  If fatigue continues to be present after the above 
measures, neurostimulants like Methylphenidate, D-Methylphenidate and armodafinil can 
be considered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXTRA PULMONARY 
MANIFESTATIONS OF 
SARCOIDOSIS: 
 
Sarcoidosis involves the lungs in 90% of patients but can involve virtually any organ or 
system in the body. Our secondary objective of the study was to look at the prevalence of 
extra-pulmonary manifestations in patients with Pulmonary Sarcoidosis who presented to 
our department.  Some studies state that extra-pulmonary manifestations in Sarcoidosis can 
be as high of 50% to 65%(57)(58).  Extra-pulmonary manifestations almost always present 
with concurrent Pulmonary involvement and is rarely seen alone.  Following is the list of 
extra-pulmonary manifestations in decreasing order of prevalence: 
1. Skin (15-25%),  
2. Eye ( 10-15%), 
3.  Liver (10-15%), 
4.  Calcium(10-15%),   
5. Spleen (5-10%),  
6. Neurologic (2-5%),  
7. Parotid/ Salivary gland (2-5%),  
8. Bone marrow (2-5%), 
9.  ENT (3%),  
10.  Cardiac (2-3%),  
11. Renal (0-1%), 
12.  Bones & Joints (0.5%) Muscle (0.4 %). 
 Recommended screening tests to identify extra-pulmonary manifestation of Sarcoidosis 
should include the following(58): 
1. History (occupational and environmental exposure, symptoms) 
 
2. Physical examination 
 
3. Poster anterior chest x-ray 
 
4. Pulmonary function tests: spirometry, DLCO 
 
5. Peripheral blood counts: white blood cells, red blood cells, 
Platelets 
 
6. Serum chemistries: calcium – serum and 24hr urinary levels, liver enzymes (alanine 
aminotransferase, aspartate aminotransferase, alkaline 
Phosphatase); creatinine, blood urea nitrogen 
 
7. Urine analysis 
 
8. Electrocardiogram 
 
9. Routine ophthalmologic and dermatologic examination 
 
Identifying and managing extra-pulmonary manifestations in Sarcoidosis patients is 
important in final outcome and prognosis of patients 
 
 
 
 
 
 
 Skin: 
 
Naming of Sarcoidosis was based on skin lesions which were Sarcoma like. 
Dermatological manifestation of Sarcoidosis is the most common extra-pulmonary 
manifestation of Sarcoidosis.  They may present at any time of the illness, starting from 
presentation with a skin lesion instead of Pulmonary symptoms or late in the course of 
disease(59).   In various up to 35% of dermatological manifestations were 
reported(60)(61)(62).   Female preponderance for skin involvement has been reported(60).  
Not all skin lesions are specific for Sarcoidosis, only a tissue biopsy from the lesion showing 
non-caseating granuloma can be taken as significant proof of Sarcoidosis causing the lesion. 
Following is the list of cutaneous manifestations of Sarcoidosis: 
 
Lupus pernio:  
Affects the cheeks, nose, ears and lips, more common in women, more common above the 
age of 40(59). It is an indolent, red-purple, violaceous lesion. It is considered as one of the 
most specific lesions suggestive of Sarcoidosis(63).  
 
Maculopapular lesion: 
 They are the most common manifestation in Sarcoidosis, they appear red-brown to purple, 
less than 1cm, presenting as an infiltrative lesion(59). Compared to Lupus pernio, prognosis 
of this type of manifestation is a favourable one. 
Erythema nodosum:  
Seen in around 10% of patients(6), they are elevated red round patches, which are painful, 
not specific for Sarcoidosis, it can be seen in other diseases but is a common manifestation 
of Sarcoidosis as well(59).   Lofgren’s syndrome as an acute presentation of Sarcoidosis with 
the triad of Erythema nodosum, Polyarthralgia and Hilar adeonopathy(64) with known 
association to HLA-DRB1*03. 
 
Plaques:  
They are round or oval in shape, ranging from millimetres to centimetres, another common 
manifestation of Sarcoidosis with a better prognosis(65) 
 
Granuloma annularae:  
Uncommon presentation, they are annular lesions and because of the granulomatous 
aetiology, called as Granuloma annularae.(59) 
 
Psoriasiform lesions: 
 Scaly, follicular lesions like Psoriasis can be seen in Sarcoidosis, but It is important to rule 
out co-existing Psoriasis as they may present together(66) 
 
Vitiligo: Autoimmune background of Sarcoidosis is well-known and can manifest as Vitiligo 
also due to its auto-immune nature(59). 
Other skin lesions which can be seen in Sarcoidosis are Subcutaneous nodules, reactivation 
of an old scar tissue, foreign body manifestation(59) 
 
Diagnosis and Treatment of Cutaneous Sarcoidosis: 
Diagnosis is based upon the tissue obtained from the lesion showing non caseating 
granulomas.   In all cases of cutaneous Sarcoidosis effort to identify systemic involvement 
should be done(59). A punch biopsy should not be attempted in a case of Erythema 
nodosum(67). 
Treatment depends on the type of skin lesion and other factors like area of involvement and 
symptoms. Harmless skin lesions and those that do not cause disfiguration need not be 
treated(57).   
Choice of therapy: Commonly used drugs in management of cutaneous Sarcoidosis are 
Glucocorticoids – Local and Systemic 
Antimalarial – Chloroquine and Hydroxychloroquine 
Methotrexate 
 
 
There are no studies to compare the efficacy of the aforementioned drugs in cutaneous 
Sarcoidosis.   Local corticosteroids are impractical to use if the lesion is extensive (57).  
Systemic steroids can be administered in severe cases. 
Lupus pernio, a variant of Sarcoidosis manifestation warrants treatment, since it is 
disfiguring, progressive and is associated with a poorer prognosis (57).  TNF Alpha inhibitors 
like Infliximab have been used in Lupus Pernio(68)(69). 
It can be thus concluded that Dermatological manifestations are very common among 
patients with Sarcoidosis, though it might not require treatment always when present.  Only 
lesions which causes symptoms, disfigurement or can be associated with a poor prognosis 
needs to be treated.  All patients with Dermatological manifestation as the presenting 
symptom, systemic Sarcoidosis should be looked for, since it rarely presents as a single 
organ involvement. 
 
 
 
 
 
 
 
 
 
 
 
 
Ophthalmological manifestations: 
 
After lung and Skin, the third organ to be affected in Sarcoidosis is the Eye.  It is seen in 
about 25 -50% of patients with Pulmonary Sarcoidosis(70), a study states the prevalence of 
ocular manifestation being as high as 70% in Japanese(71).  Ocular manifestation has been 
found to have variable prevalence in different races (69).  In the western population More 
severe disease in seen in Blacks(69) and chronic or asymptomatic diseases are more 
commonly seen in Whites(72).  
 They may have varied presentation – They may be the first symptom patient presents with 
in Sarcoidosis, can present years before systemic manifestations(70).  Following are the 
manifestations of Sarcoidosis in the Eye: 
 
Uveitis – Anterior and Posterior(73)(71)(74):   
Uveitis is the most common ophthalmological presentation in Sarcoidosis(6), anterior uveitis 
being more common than posterior uveitis.  Anterior uveitis is usually granulomatous and 
has a chronic course compared to posterior uveitis(70). One of third of patients might be 
asymptomatic, but others present with Pain, redness, decreased visual acuity and 
photophobia which can be bothersome and might be the presenting symptom of 
Sarcoidosis. 
 
 
 
Cystoid macular oedema(73)(71)(74):  
Cystoid macular oedema usually results due to chronic uveitis.  It is found to be refractory to 
the anti-inflammatory drugs which are used in Sarcoidosis and is vital in deciding the visual 
prognosis if present.(70) 
 
Visual loss(73)(71)(74):  
Visual loss may be the presenting symptom but is not specific for Sarcoidosis. 
 
Conjunctival Nodules:  
Conjunctival nodules are seen in up to 40% patients who have involvement of Eye(75) 
Lacrimal gland swelling(73)(71)(74): Frequency of lacrimal gland being involved ranges from 
7 to 69% and present with nasal stuffiness and epiphora(68). 
 
Optic neuritis(73)(71)(74): Optic neuropathy is a relatively rare complication of Sarcoidosis. 
Patient presents with papilledema, papillitis and occasionally with granulomas on the optic 
head.  There may be inadequate response to therapy and they develop optic atrophy. 
Systemic therapy may be required in patients with optic nerve involvement.  Anti TNF Alpha 
blockers like Infliximab have to be used and have been found to be useful in treating 
patients who develop optic neuropathy. 
 
Orbital disease:  
Orbital disease is more commonly seen in elderly patients. It may involve the adnexa and 
the orbit.  This leads to entrapment of the eye associated with diplopia. 
 
Ocular biopsy demonstrating granuloma (73)(71)(74):  
Occasionally only through an ocular biopsy is diagnostic of granulomatous invasion of eye by 
Sarcoidosis. 
 
Miscellaneous manifestations: Patients with ocular Sarcoidosis in few case may present with 
Scleritis, Glaucoma or Cataract. 
 
Diagnosis of Ocular Sarcoidosis: 
Findings on an ocular examination suggestive of Ocular Sarcoidosis are the following: 
 Mutton fat keratitic precipitates 
 Iris nodules – koeppa / Bussaca 
 Trabecular meshwork nodules 
 Tent shaped peripheral anterior synechiae 
 Snowballs, string of pearls vitreous opacities 
 Multiple active or atrophic chorio-retinal peripheral lesions 
 Nodular or segmental periphlebitis – “candle wax drippings” 
 Optic disc nodules 
 Retinal macroaneurysms 
 
Definitive diagnosis of ocular Sarcoidosis would be an ocular biopsy but is not possible or 
required in all cases.  ACCESS study used to define organ involvement in patients with 
Sarcoidosis lays down the following criteria: 
 
Definition of Ocular Involvement in Patient with Biopsy-Confirmed Sarcoidosis(76) 
 
 
Definite ocular sarcoidosis 
 
 Uveitis 
 Lacrimal gland swelling 
 Optic neuritis 
 Ocular biopsy demonstrating 
 Granulomas 
 
 
Probable ocular sarcoidosis 
 
 Blindness 
 
 
 
 
 
International criteria used for diagnosing Sarcoidosis if biopsy is not possible is by the 
following Strategy(77): 
 
 
 
 Treatment of ocular Sarcoidosis: 
A stepwise treatment of ocular Sarcoidosis is advised.  It is advisable to start with topical 
steroids in patients with mild uvieitis, in most cases control can be achieved with that. In 
those control is still not possible or those who have a severe disease, topical and intra-
ocular steroids can be used.  If still control is desired, systemic corticosteroids are indicated. 
Other drugs which can be used are cytotoxic drugs like Methotrexate, Leflunomide, 
Azathioprine and Mycophenolate. When even with Steroids and Cytotoxic therapy control is 
not achieved TNF Alpha inhibitors like Infliximab can be used(72). There are studies on the 
human monoclonal antibody against TNF Alpha, Adalimumab in treating refractory cases of 
eye involvement even after treatment with infliximab(55). 
 
 
 
 
 
 
  
Liver involvement: 
 
Next organ to be involved as part of the extra-pulmonary spectrum of Sarcoidosis 
involvement is the Liver.  Prevalence of liver involvement in Sarcoidosis also has a varied 
range.   ACCESS trial looking at various organ involvement reported a prevalence of 
11.6%(79).  Some studies reveal a higher prevalence of liver involvement ranging from 50-
90%(80)(5).  Patients with liver involvement are usually asymptomatic and very few are 
progressive in nature.  It is seen that 40-80% of patients, it is only a histological diagnosis, 
25-35% will have abnormal liver function tests, 5-15% of them will present with symptoms 
like abdominal pain, hepatomegaly, pruritus, nausea, vomiting, weight loss and jaundice. 
Only a small percentage of them – 1% develop progressive and have serious consequences.  
But it is important to identify the presence of liver involvement at the time of diagnosis of 
Sarcoidosis.  The most commonly missed finding is that of elevated liver enzymes.   
 
Though most patients are asymptomatic and does not require treatment a small portion of 
the patients may present with one of the following: 
 Chronic Cholestatic disease 
 Portal Hypertension 
 Cirrhosis 
 
  
 
Sarcoidosis can affect the liver and present pathologically in the form of (81) 
Cholestasis: 
 Acute cholangitis 
 Periductal fibrosis 
 Ductopenia 
 
It may present as a necro-inflammatory lesion with: 
 Focal necrosis with mono nuclear infiltration 
 
Fibrosis due to Sarcoidosis in liver presents as: 
 Peri-portal  
 bridging 
 cirrhosis 
 
 
 
Vascular changes seen are: 
 Sinusoidal dilatation 
 Granulomatous venulitis 
 Nodular regenerative hyperplasia 
Diagnosis of Liver Sarcoidosis not always warrants a biopsy from the liver. In a patient who 
has been diagnosed with Sarcoidosis has elevated liver enzymes i.e. alkaline phosphatase 
and Transaminases, or if the radiological finding is characteristic of Sarcoidosis in the liver, 
liver biopsy is not required to diagnose Sarcoidosis involvement of the liver.  The most 
common radiological manifestation of Liver Sarcoidosis is Hepatomegaly(82).  CT of the 
abdomen in some patients may reveal multiple low density intra-hepatic septa which are 
said to be characteristic presentation of Sarcoidosis (81).  5-19 % of patients are found to 
have focal nodules which are considered to be granulomas. These nodules characteristically 
range from 1-2cm , innumerable in number and are diffusely spread in the liver.  These 
nodules do not have any peripheral enhancement (81).  Sarcoidosis may involve the biliary 
tree as well where it mimics Primary biliary Cirrhosis closely and needs to be ruled out.  The 
main differentiating feature is the absence of Ant mitochondrial antibodies (81). 
 
Treatment of Liver Sarcoidosis: 
Not all patients with Liver Sarcoidosis warrant therapy. Patients who have the following 
need to be treated: 
 Symptoms or progressive organ damage 
 Abnormal synthetic function 
 Worsening Liver enzymes 
 Abdominal pain, Jaundice with evidence of cholestasis 
Other patients do not require treatment but a careful watch on Liver function tests with 
testing once in at least 3 months is recommended(5).  
Therapy has been tried with the following: 
 Corticosteroids 
 Immunosuppressive 
 Ursodeoxycholic acid 
 Liver transplantation 
 
Corticosteroids have been found to be useful in patients with Liver sarcoidosis, some studies 
have reported a mixed response and a drawback noticed is its inability to prevent Portal 
Hypertension(80), hence corticosteroids need to be given only when suspected organ failure 
is present (78).  
 
Immunosuppresives like Azathioprine may in itself cause liver damage, so avoided in 
patients with Liver sarcoidosis.  There are not sufficient reports on treatment of liver 
sarcoidosis with TNF Alpha inhibitors. 
 
 
Ursode-oxycholic acid is the proven treatment for cholestatic disease.  In all patients with 
suspected Cholestatic disease, Ursodeoxycholic acid should be prescribed. It has been 
shown to have significant improvement in liver function markers which are considered as a 
poor prognostic factor in patients with Liver sarcoidosis. (80) 
 
Liver transplantation: 
 Liver transplantation is the definitive treatment in patients who have overt liver failure.  
(79) It should be reserved only for these patients as those who are on ursodeoxycholic acid 
or corticosteroids may still worsen and develop Cirrhosis. 
 
 
 
 
 
 
 
 
 
 Spleen: 
 
Involvement of spleen by Sarcoidosis is seen in about 5-10 % of patients.  Most common 
involvement of Sarcoidosis is in the form of Splenomegaly. 30-60% of cases are 
asymptomatic(83).  Most common presentation like liver involvement is the presence of 
splenomegaly (84).  It may be found in the clinical examination of the patients or in imaging 
of the abdomen. Massive splenomegaly is rare in patients with Sarcoidosis, but can be seen 
(82). All patients with splenic involvement don’t have a poor prognosis and don’t require 
treatment.  Spleen involvement is most commonly seen in association with liver 
involvement. In some cases it can cause abdominal discomfort(85).  
 
Most of them have good prognosis.  A fine needle aspiration cytology may be obtained form 
the spleen in case of doubt of spleen involvement due to some other aetiology, which is 
rarely required as sarcoidosis presenting only with spleen involvement is rare. A cytology 
from the spleen is considered to be characteristic of Sarcoid involvement of spleen if it 
showed clusters of epitheliod cells (84). 
 
 
 
 
 
 Treatment in the form of splenectomy  or corticosteroids is rarely required, it should be 
used only for patients with 
Hypersplenism 
Splenic rupture 
Severe cytopenia 
Prognosis of patients with Splenic sarcoidosis is good and most of the patients do not 
require treatment. Size of spleen has been seen to decrease variably.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neurological manifestations: 
 
Next common organ to be involved in Sarcoidosis is the Central nervous system, spinal cord 
and nerves.  Prevalence of Neurosarcoidosis is around 5%(86)(87)(88). Some studies state a 
prevalence of up to 16%(89). 
 
Neurological symptoms in a patient with Sarcoidosis can be due to any of the following 
 Non Sarcoidosis disease 
 It may be because of the granulomatous inflammation of the nervous system when it 
is called as Neuro-Sarcoidosis 
 It can be because of Sarcoidosis but without causing granulomatous inflammation 
 Patient may come with a neurological symptom because of the therapy or due to 
immunological alterations seen in Sarcoidosis. 
 
Commonest Neurological symptoms with which Sarcoidosis patients present are: 
 Headache 
 Clumsiness 
 Concentration problems 
 Numbness 
 Memory problems 
 History of facial weakness 
 
 Most common manifestation of neuro-sarcoidosis is in the form of Cranial nerve palsy, facial 
nerve being the most common observed palsy(88).   
Other manifestations of Sarcoidosis affecting the Nervous system may be myriad.  Following 
is the list of range of neurological presentation when in an appropriate clinical setting, 
sarcoidosis should be considered as a possibility(88); 
 Aseptic meningitis 
 Encephalopathy 
 Vasculopathy 
 Mass lesions 
 Seizures 
 Hydro-cephalous 
 Peripheral neuropathy 
 Myopathy 
 Myelopathy 
 Hypothalamic – Pituitary disorders 
Nervous system Sarcoidosis may present or leave a patient with High morbidity and hence 
an early suspicion and early diagnosis is always mandatory (88)(89).  Severe forms of 
presentation are seen in acute stages of Sarcoidosis and Chronic Sarcoidosis usually present 
with peripheral nerve involvement and myopathy(86). 
 
 
 Diagnosis of Neuro-Sarcoidosis: 
Diagnosis of neuro-Sarcoidosis requires tissue showing granulomatous inflammation. In 
1999, a criteria was devised to diagnose Neuro-sarcoidosis to Definite, Probable and 
Possible as three criteria(90).  
 
 Definite:   
Diagnosis based on Histo-pathology with a clinical picture of neuro-sarcoidosis and 
other disease has been ruled out. 
 
 Probable:   
Clinical setting supports Sarcoidosis along with labarotory evidence of CNS 
inflammation due to Sarcoidosis i.e. elevated CSF Protein levels, oligoclonal bands, 
neurological evidence consistent with Sarcoidosis in imaging done (MRI) and 
systemic proof of Sarcoidosis in the form of positive histology from another site, 
positive Kveim’s test, Indirect markers like high ACE levels, Gallium scans suggestive 
of Sarcoidosis and chest imaging in accordance with Sarcoidosis. 
 
 Possible:  
When above criteria is not fulfilled but exclusion of other diseases have been done 
and clinical setting strongly suggests Neuro-sarcoidosis. 
 
 Radiological diagnosis: 
MRI is the most relevant imaging modality used for Neurosarcoidosis. Following are the 
various presentations which can be appreciated in MRI in a case of Neuro-sarcoidosis(91): 
 Dural meningeal Sarcoid 
 Lepto-meningeal Sarcoid 
 Enhancing brain parenchymal lesion 
 Non-enhancing brain parenchymal lesions 
 Spinal cord and nerve root involvement 
 Cranial nerve involvement 
Neurological manifestation may suggest prognosis of Sarcoidosis in them.  It is important to 
characterise the type of lesion. It is seen that patients who have a cranial nerve lesion, a 
non-enhancing lesions or a Dura based lesion had better prognosis in comparison with 
spinal lesions, Brain parenchymal enhancing lesions or Lepto-meningeal involvement. MRI 
also proves to be good in follow up of patients showing significant resolution in lesions for 
patients those who respond to treatment(91).  
 
Treatment of Neuro-Sarcoidosis: 
Patients those who have been found to have Neuro-sarcoidosis in the central or peripheral 
nervous system and are symptomatic are always offered treatment considering significant 
mortality and morbidity.  
Drugs which have been used in treatment of Neuro-Sarcoidosis are(90): 
 Corticosteroids 
 Infliximab 
 Methotrexate 
 Azathioprine 
 Mycophenolate 
 Cyclophosphamide 
 Concomitant Anti-convulsant in patients with seizures 
 
Drugs which have been shown to be beneficial only in case reports are(90): 
 Chlorambucil 
 Radiotherapy 
It is advised to start cortico-steroids at higher dosage and then taper gradually. Studies show 
higher response rate with drugs like Cyclophosphamide and Methotrexate(92). Prognosis of 
neurosarcoidosis is found to be poorer compared with other extra-pulmonary 
manifestations due to its higher morbidity and mortality.  Prognosis with peripheral nervous 
system involvement is better than those with central nervous system involvement(86). 
 
 
 
 
Parotid/ salivary gland manifestation: 
 
Parotid gland / salivary gland involvement in Sarcoidosis is seen in up to 6% of patients(93). 
Following are the characteristics of parotid / salivary gland involvement in Sarcoidosis (93): 
 Presents in the age group of 20-40 years 
 More common in women 
 73% of them may present with bilateral disease 
 
Most common symptom of involvement of these glands is an asymptomatic enlargement of 
both parotid glands.  Other clinical presentations can be(94): 
 Xerostomia 
 Dysguesia 
 Oral burning 
 Xerophthalmia 
 
Sicca syndrome can be associated with Sarcoidosis. 
Heerfordt’s syndrome:  
When patients with Sarcoidosis present with uveitis, enlargement of the parotid glands and 
in some patients with facial nerve paralysis(95).  Diagnosis of Heerfordt’s syndrome also 
requires a histopathological diagnosis (95).   
Diagnosis of parotid and salivary gland involvement will require a tissue from minor salivary 
glands showing non-caseating granulomatous inflammation(96).  Gallium scan done is also 
found to be specific for patients who have minor salivary gland involvement.  In patients 
who have biopsy proven non-caseating granulomas will have gallium uptake (96). 
 
Bio-chemical studies done on the saliva from parotid gland of patients who have Sarcoidosis 
of the parotid show the following features(97): 
 Decreased level of alpha amylase 
 Increased albumin and Lysozyme 
This suggests a pathological involvement if the gland due to inflammation leading to 
transfer of constituents from serum to saliva (97). 
 
Panda sign: 
Sign described on a radio-gallium scintigraphy when lacrimal, submandibular and Parotid 
glands are involved(98).  This sign is found to be sensitive for Sarcoidosis. 
Rarely parotid gland or minor gland involvement in Sarcoidosis requires treatment. Chronic 
sialadaenitis may develop in few patients in who surgical intervention might be required. 
 
 
 
  
Bone marrow involvement: 
 
Prevalence is around 5% in patients with Sarcoidosis 
Diagnosis of bone marrow involvement in Sarcoidosis is always with the help of biopsy from 
the marrow demonstrating non-caseating granulomas (99) .  Patients with Sarcoidosis 
involvement of the bone marrow may present with derangement of any of the cell 
lines(100): 
 Anaemia 
 Leucopoenia 
 Lymphopenia 
 
They found anaemia to be the most common presentation of Sarcoidosis affecting the bone 
marrow.  Any patient in whom Sarcoidosis is suspected and has anaemia, leucopoenia or 
lymphopenia bone marrow biopsy has to be performed to rule out Sarcoidosis involvement 
of the marrow. 
 
F-18 FDG PET / CT is found to have a higher sensitivity to identify Sarcoidosis involvement of 
the marrow(101)(102).  
Treatment of patients with Sarcoidosis affecting the bone marrow is treatment with steroids 
which is used for systemic therapy(103).  It has been seen that anaemia in patients which 
are due to Sarcoidosis reverse once treated with Sarcoidosis and might not require 
replacement.  Work up of anaemia does not yield anaemia of chronic disease as seen in 
Tuberculosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ENT Manifestations: 
 
Ear, nose and throat can also be involved in patients with Sarcoidosis.   
Patients may be mistaken to have allergic rhinitis if a clinical suspicion of Sarcoidosis or 
other granulomatous diseases are not thought of since patients with Sarcoidosis affecting 
the Ear, Nose and Throat may present with(104) 
 Rhinorrhoea 
 Nasal obstruction  
 Crusting 
 Hearing loss 
On examination findings which are non-specific for Sarcoidosis , but may be found are(105) 
 Nasal polyps 
 Erythematous Nodules 
 Granulations on the turbinate 
 Turbino-septal synechiae 
 Septal deviation 
 They may involve the maxillary sinuses along with nasal findings and present as Sino-
nasal Sarcoidosis 
 Nasopharynx involvement may be in the form of a pseudotumour 
 
Gallium Scan may pick up involvement of sino-nasal sarcoidosis. 
CT Done in them will have findings as noted in clinical examination of the patient with 
turbinate erosion, septal deviation and mucosal thickening of the sinuses when they are 
involved. 
Good ENT examination and biopsy from the site will usually provide the diagnosis of sino-
nasal Sarcoidosis. 
Hearing loss in patients with Sarcoidosis may be because of involvement of the ear, but it 
may be due to central nervous system as well(106)(107). 
 
 
 
 
 
 
 
 
 
 
 
 Cardiac manifestations: 
 
Next important organ which can be involved in Sarcoidosis is heart. Prevalence of cardiac 
involvement in Sarcoidosis is found to be about 5% (108).  It is more commonly seen in 
Japanese and American population reaching up to 70-85% of cases(109).  Common 
manifestations of cardiac sarcoidosis are(110): 
 Ventricular arrhythmias 
 Conduction blocks 
 Pericardial effusion 
 Congestive heart failure 
 Pulmonary hypertension 
 Ventricular aneurysm 
 Sudden cardiac death 
 Angina pectoris 
 Valvular dysfunction 
 
 
 
 
Cardiac involvement may be the presenting symptom in few cases, in most it either presents 
along with Lung involvement or just after diagnosis of pulmonary sarcoidosis. 
Most case of Sarcoidosis affected hearts are found only during autopsy.(109).     
In patients who has proven extra-cardiac sarcoidosis, in the event of patient developing 
cardiac failure or arrhythmias , cardiac involvement should always be considered(111).  
Patients who have dyspnoea which is not proportionate to the lung involvement should also 
be evaluated for cardiac sarcoidosis.   
Pathologically cardiac sarcoidosis is seen to involve myocardium with autopsies 
demonstrating non caseating granulomas suggestive of sarcoidosis.  Most patients were 
found to have myocardial involvement.  Ventricles are more commonly found to be involved 
compared to atrium, but all chambers are involved.   
Complete heart block in a young patient should always raise the suspicion of cardiac 
sarcoidosis in those patients.   
They may clinically present as dilated cardiomyopathy as well. 
Another rare presentation is the triad of congestive heart failure, malignant ventricular 
arrhythmia and high degree AV block (111), it needs to be differentiated from giant cell 
myocarditis before labelling as Cardiac sarcoidosis. 
 
 
 
Diagnosis of cardiac sarcoidosis: 
ECG is the first step in evaluating patients suspected to have cardiac sarcoidosis.  Only 15% 
of patients who have cardiac sarcoidosis are found to have ECG changes at presentation. 
ECG changes also vary with severity of disease.  More severe the disease earlier the ECG 
manifestation is observed(109).  First step in diagnosis would be an ECG, if still strong 
clinical suspicion persists, next step in evaluating a patient of cardiac sarcoidosis is with 
Holter monitoring and 2D Echocardiography is must.  Echocardiography may reveal a low 
ejection fraction suggestive of cardiac failure.  2D Echocardiography being a cheaper and 
non-invasive investigation had been commonly used in diagnosis of patients with 
Sarcoidosis.  Sensitivity of Echocardiography can be increased by doing a stress 
echocardiography as well.   
Next step in evaluating a patient with cardiac sarcoidosis is Radiological investigations which 
includes CT, MRI or Gallium scan. 
CT is not the recommended mode of modality in imaging the heart, myocardial thinning 
may be the only feature seen in CT(112). 
MRI is the modality of choice.  Following are the findings which can be seen in Cardiac 
sarcoidosis (112): 
 Trans mural or mid-wall delayed enhancement 
 Nodular hyper intense foci on t2 weighted imaging 
 Areas of myocardium may be found to be thickened 
Other modalities which are used are the thallium and gallium scans. It should be reserved 
for only patients who have cardiac symptoms and a high clinical suspicion of Sarcoidosis is 
present. 
 
Invasive diagnostic procedures: 
Cardiac catheterisation to look for co-existent coronary artery disease can be done. 
End myocardial biopsy which was started in 1962, the biopsy is usually obtained from the 
right ventricle, though left ventricle is found to have the most common involvement.  
Sample being non representative  is a possibility in such a setting(109). 
To diagnose a patient with Cardiac sarcoidosis, requirements would be to obtain histological 
proof of non-caseating granulomas along with one of the clinical and/or radiological 
features mentioned above. 
 
Management: 
As with other organ involvement, corticosteroids remain the mainstay of treatment.  There 
can be a higher rate of mortality if patients are not carefully monitored and observed. 
Corticosteroids have been found to have a good prognosis in patients with Cardiac 
sarcoidosis if treated early. 
 
Anti-arrhythmics may be required in patients who present with arrhythmia. Occasionally an 
in situ automatic implantable cardioverter defibrillator might have to be placed, the decision 
to place one of those is patient based and might not be warranted in those who revert with 
medical management. 
 
Immunosuppressive agents have been tried in cardiac sarcoidosis.  Following are the drugs 
which have been used: 
 Methotrexate 
 Azathioprine 
 Cycloserine 
 Thalidomide 
 Pentoxifylline 
 Infliximab 
 Hydroxy-chloroquine 
 
Some people have combined an immune-suppressant to corticosteroids to decrease the 
dose of long term steroids.(109). 
 
Other options available for patients with Cardiac sarcoidosis are Heart transplantation. It is 
recommended for only those who have severe and recurrent heart failure and do not 
respond to conventional medical therapy (109).  Sarcoidosis in the heart transplanted is also 
a possibility, but can be treated sufficiently with Steroids. 
Prognosis of Cardiac sarcoidosis is not very well defined and it depends on early diagnosis 
and treatment.  
Patients who are started on cortico-steroids are found to have survival rate of 75% in a 5 
year follow up study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bone / Joint and Muscle involvement: 
 
Patients with Pulmonary sarcoidosis can have involvement of Bone/Joint and Muscle 
involvement.  It is found to be low at the initial presentation 1% and gradually the 
prevalence of bone, joint and muscle involvement may go up to 13%(113).  Osteo-articular 
manifestations may or may not be specific to Sarcoidosis. 
 
Following are the Rheumatologic manifestations seen in patients with Sarcoidosis: 
Acute Sarcoid arthritis 
Chronic Sarcoid arthritis 
Sarcoid synovial and tendinous involvement 
Asymptomatic muscle involvement has been observed in 25-75% of patients.(114) 
Acute polymyositis like syndrome 
Tumorous sarcoidosis of the Muscles 
Chronic progressive myopathy 
Bones – hands are the most commonly affected structures(115) 
Lace like pattern may be seen 
Sclerotic bone lesions 
Osteopenia / osteoporosis 
 Significant skeletal muscle weakness has been seen in patients with Sarcoidosis(45) which 
may contribute to fatigue in these patients. 
Diagnosis of musculoskeletal involvement is done with the help of history suggestive of the 
same along with tissue diagnosis of non caseating granuloma in a biopsy specimen. 
 
Treatment of patients with musculo-skeletal involvement in Sarcoidosis is according to the 
symptomatology of the patients.  Those who have mild arthritis can be managed with 
NSAIDs and cold packs(113).  Systemic cortico-steroids are also found to be effective.  There 
are studies stating colchicine as another option in treating these patients. 
 
Prognosis of joint involvement in Sarcoidosis is considered to be good with recovery seen in 
1-6 months depending on the severity of the disease. 
Patients who have a chronic destructive synovitis may need intraarticular steroids. 
Patients with bone involvement have been seen to have a poorer prognosis, with the lesions 
being unresponsive to therapy 
 
 
 
 Calcium / Renal manifestations: 
 
Calcium metabolism is found to be deranged in patients with Sarcoidosis.  
Prevalence of calcium derangements in serum or urine in patients with Sarcoidosis varies 
from 5-50% (116). 
Patients with these derangements may present with one of the following: 
Hypercalcemia 
Hypercalciuria 
Decreased bone density 
Increased serum concentration 1,25 dihydroxy cholecalciferol(117) 
Very few case reports may be found where patients do not have Lung involvement but 
present only with calcium metabolism derangement.(118) 
 
Following are the pathogenesis of Sarcoidosis affecting calcium metabolism: 
Extra-renal synthesis of calcitriol causing derangement in calcium homeostasis 
Alteration in activity of PTH – Parathormone 
PTH related peptide expression 
Clinically hypercalciuria is seen in up to 62% of patients with Sarcoidosis.  Hypercalcemia to 
cause significant symptoms is not commonly seen.  
Nephrocalcinosis due to long standing hypercalciuria may be seen in some patients  
Some of them may present with Nephrolithiasis, renal failure which is seen to be rare in 
patients with Sarcoidosis. 
 
Investigations which are required when evaluating a patient with suspected renal 
involvement due to Sarcoidosis are : 
 Serum Calcium and albumin 
 24 hour urinary collection for calcium > 400 considered to be significant 
 Creatinine to assess the functional status of the kidneys 
 Ultrasonography of the abdomen to look for Nephrolithiasis and Nephrocalcinosis 
 
Management: 
Patients started on steroids seem to show good improvement except for bone mineral 
density which might be reduces further. 
There are reports of thiazide diuretic used in management on hypercalcuria, but has not 
been accepted worldwide. 
 
Surgical intervention for nephrolithiasis should be continued as per indications for any other 
aetiology. 
Their prognosis is not considered to be poor if treated adequately  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methodology: 
 
Sarcoidosis is a multi-system disorder, mainly involving the lungs.  Other organ involvement  
is as mentioned in the previous section on review of literature.  This study was designed to  
assess the importance of fatigue in patients diagnosed with Pulmonary Sarcoidosis.  It was  
also designed to assess the prevalence of other extra-pulmonary involvement.  Aims and  
objectives of the study are mentioned below 
 
 
 
Aim –  
 
Assessment of fatigue and other extra-pulmonary manifestations in patients  
diagnosed with Pulmonary Sarcoidosis  
 
Objectives –  
 
Primary:  
 
Prevalence of Fatigue in all patients diagnosed with Sarcoidosis in the department of Pulmonary 
Medicine.  
 Secondary: 
 
 Assess the extra-pulmonary manifestations of Sarcoidosis in the same Cohort of patients 
  
We planned to include all patients who are diagnosed with Pulmonary Sarcoidosis 
to be included in the study.  Plan was to calculate the prevalence of Fatigue in all patients  
diagnosed with Pulmonary sarcoidosis.  To calculate the same,  literature of review done  
prior to inception of the study revealed an approximate prevalence of 50-70% in previous 
studies of same nature.  With help of a statistician, sample size was calculated which is given 
as follows: 
 
 
Single Proportion - Absolute Precision 
Expected  Proportion 0.5 0.5 0.5 
Precision (%) 10 15 17.5 
Desired confidence level  (1- alpha) % 95 95 95 
Required sample size 96 43 31 
 
 
 To obtain a minimum of 43 patients to get results with a precision of 15% was planned. 
To get the required number of patients it was estimated that approximately 1500 patients  
need to be screened to diagnose around 40 patients with Sarcoidosis.  We decided to  
include as many patients as possible during the period of January 2014 to August 2014. 
We managed to include 75 patients into the study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 STROBE Figure showing the flow of patients into the study: 
 
 
                   Number of patients in Pulmonary medicine department =  3000 
 
 
 
                   Number of patients with Pulmonary Sarcoidosis =   85 
 
 
 
 
        Old patients =     57                                             New patients = 28 
 
 
 
As mentioned above we included 75 patients with Pulmonary Sarcoidosis out of 
which  - 28 Were new patients and   57 were old patients.  We decided to include 
patients with histopathologically proven Sarcoidosis from the age group of 15 to 100 
Patients who were seen in outpatient or patients who were admitted were also 
included.  They were included irrespective of their treatment status.  Both treatment 
naïve and Patients who were on treatment were included with careful 
documentation of their treatment status.   
A pulmonary histopathological diagnosis was not always necessary, diagnosis from 
biopsy of any other organ ( e.g.  Skin, Liver, Bone marrow) along with clinical and 
radiological relevant pulmonary features were considered sufficient.   
Summarising the inclusion criteria: 
 
Inclusion criteria:   
All patients with diagnosed Sarcoidosis, clinically and biopsy 
            proven (both treatment naïve and on treatment) , as outpatient and inpatient in the  
            department of Pulmonary Medicine in CMC Vellore from the period of January 2014  
             to August 2014. 
 
Since the primary objective of the study was to look at the prevalence of fatigue,  
              After review of literature as mentioned in the previous section, we designed the 
              Exclusion criteria to avoid confounding. 
 
Exclusion criteria:  
 
1.Anaemia( Haemoglobin levels of less than 10gm% in males and 8gm% in females) – 
Since anemia has been to shown to cause a certain level of fatigue, to avoid 
confounding, all patient who had anemia 
 with the above mentioned levels were excluded from analysis. 
 
 
 
 2. Hypothyroidism :- 
Hypothyroidism can present with fatigue being a common symptom, it was decided 
that patients who do not have hypothyroidism were Included for the study, or 
patients who have been diagnosed with hypothyroidism 
but are on replacement with TSH levels being less than 8 were included, other had to 
be excluded to avoid confounding. 
 
 
3.  Existing malignancy (diagnosed and/or on treatment) :-   
Malignancy has been a proven cause of fatigue and was hence considered exclusion 
criteria to avoid confounding. All patients who have a diagnosis of malignancy at the 
time of inclusion into study were excluded for assessment of fatigue. 
Even patients who were on treatment for any malignancy were excluded for the 
same reason. 
 
4.Tuberculosis :- 
Tuberculosis of any organ is known to manifest with fatigue which 
Can act as a confounding factor in our study hence all patients with Tuberculosis, or  
Patients who had concurrent tuberculosis, or patients who were labelled as probable 
Sarcoidosis due to doubtful co-existing tuberculosis, and/or were put on both  
Anti- tuberculous therapy and treatment for Sarcoidosis were also excluded for 
the same reason. 
 
 After making sure that a patient does not meet any exclusion criteria, study done 
was explained to him/her, an informed consent was obtained; once they consented 
for taking part in the study, for details view annexure.  Once they gave consent,   
demographic details including their name, age, sex, profession, marital status were 
noted.  They were asked to fill in a questionnaire on fatigue known as ‘ Fatigue 
assessment scale’ this is a validated measure for fatigue in patients with sarcoidosis.  
The questionnaire comprises of 10 questions dealing addressing various aspects of  
both physical and mental fatigue, with the options of 1-5 in each.   
Adequate time was given to each patient and the questionnaire administered was in 
the language which the patient is fluent in.  Total score was calculated  
once the patient completed the questionnaire. A score of 22 or more was  
considered significant to indicate significant fatigue.   Details including the  
time since diagnosis and detailed treatment history was recorded.  The prevalence  
of fatigue was thus calculated. 
 
Secondary objective of the study was to assess the prevalence of  other extra-
pulmonary manifestations in the same cohort of patients. 
 
 
 
 
 
 
 The commonest organ to be involved in Sarcoidosis is the lung.  The other organs in  
Decreasing order of prevalence as per literature is as follows: 
 
1. Skin  
2. Eye 
3. Liver 
4. Spleen 
5.  Brain 
6. Parotid/Salivary gland 
7. Bone marrow 
8. ENT 
9. Heart 
10. Bone, Joint, Muscle 
11. Kidney 
 12. Hypercalcemia / Hypercalciuria 
 
Commonest extra-pulmonary organ involvement being Skin and Eye, arrangements were  
Made for all patients to be screened by a senior dermatologist and a senior  
Ophthalmologist.  Patients who already had documented  
Skin or eye involvement were not subjected to repeat examination unless the present 
condition required review.  For 5 patients Dermatological and Ophthalmogical screening  
could not be done due to personal inconveniences.   
 
Since other organ involvement was less common, basic screening tests included, system 
specific history and physical examination, an ECG was done to look for rhythm abnormalities 
- arrhythmias or heart blocks-, peripheral blood counts (WBC, Hb, Platelets) were done to 
look for bone marrow involvement, Serum and urinary Calcium levels were obtained for 
abnormalities in calcium metabolism,  Liver function tests were done to look for liver 
involvement ( Liver enzymes more than thrice the normal will be considered as abnormal), 
an ultrasound abdomen was not routinely done, but performed if the liver function tests 
were abnormal.  Urine-analysis, serum creatinine & Urea were done to look for renal 
involvement.  Any abnormality found in any of the screening tests, were followed up with 
more detailed investigations as required or referral to  concerned speciality department for 
expert opinion.  The prevalence of extra-pulmonary manifestations were finally collated in 
these patients. (Performa for extra pulmonary sarcoidosis is appended in the annexure) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS: 
 
All 75 patients recruited had pulmonary sarcoidosis, which was histo-pathologically proven. 
None of them met any of the exclusion criteria mentioned in the methods section.  The 
primary and secondary objectives were assessed in this group 
 
 
 
BASELINE CHARACTERISTICS: 
 
Baseline Characteristics of the patients are given below in Table 1.  We included 75 patients 
into the study.  Mean age of the patients were 47.27 with a standard deviation of 10.2.  As 
shown in table 2, maximum number of patients (32,47%) were in the age group of 40-49.   
There were more male patients than female patients, although in published literature, the 
disorder is described to be  slightly more common in females.  Since many patients travel 
long distances to get evaluated at CMC, part of the reason for this skew may be referral 
bias. This was a bidirectional study and included patients who were newly diagnosed as 
Pulmonary sarcoidosis and also those on follow up, who were on treatment or on post 
treatment follow up. The number of new patients included in the study was - 28 and other 
diagnosed previously were 47, 37 of whom were on steroid treatment.  Radiological staging 
of Sarcoidosis was done on all the patients, we had maximum number of patients in Stage 2 
(45 , 60%).   
Table 1 Baseline characteristics  
Age                             47.27 (10.2) 
Sex 
     Male                      41 (54.7) 
     Female                  34 (45.3) 
 
Diagnosis Status 
     New                        28 (37.3) 
     Follow up               47 (62.7) 
 
Marital Status 
      Married                   3  (4) 
      Unmarried            72  (96) 
 
Staging 
      Stage 1                   10 (13.3) 
      Stage 2                   45 (60) 
      Stage 3                   16 (21.3) 
      Stage 4                    4  (5.3) 
 
Steroids 
      Yes                           37 (49.3) 
      No                            38 (51.7) 
 
Table 1: Table showing baseline characteristics of patients with Pulmonary Sarcoidosis 
included in the study. The standard deviation for age and percentage for other variables are 
within parenthesis. 
 
 
 
 
 
 
 
Table 2 showing age distribution of the patients 
 
Age                                   Frequency ( No / Percentage) 
 
< 40 yrs                       12 (16) 
 
40 - 49 yrs                   32 (42.7) 
 
50 - 59 yrs                   22 (29.3) 
 
60+ yrs                          9 (12) 
 
 
 
 
 
Table 3 showing distribution of dose of steroids in patients on treatment, the doses are 
presented as Prednisolone equivalent 
Dose                         No / Percentage 
>40mg                           0 (0) 
 
20-39mg                        3 (8) 
 
11-19mg                       12 (32.4) 
 
0-10mg                         22 (59.4) 
 
Total                              37 
 
 
 
 
 
 
 
  
Table 4 shows duration of steroid treatment in months  
Duration                    No (%) 
 
< 6 months                 4 (10.8) 
 
6-12 months              7 (18.9) 
 
>12 months              26 (70.3) 
 
Total                          37 
 
 
Table 3 and 4 deal with the dose and duration of steroids.  Steroids due to their effect in 
causing myopathy can lead to fatigue and hence details of the duration and dose of steroids 
were captured to analyze if statistically significant association is found and whether it can be 
a confounder. .  Fifty nine percent of the patients were on less than 10mg of steroids and  
70%  of the follow up patients had been on treatment for more than a year.    
 
 
 
 
 
 
 
 PREVALENCE OF FATIGUE:   
A total of of 55 subjects(73%) were detected to have fatigue on the basis of the fatigue 
questionnaire.   
Table 5 shows the prevalence of fatigue in new vs. old patients 
                    FAS >21    FAS ≤ 21 
New               24 (85.7%)     4(14.3%) 
Old                 31 (66%)     16 (34%) 
Total              55 (73%)    20 (27%) 
 
As is evident from Table 5, patients who were newly diagnosed and had not received any 
treatment, had a higher prevalence of fatigue 85% VS 66% in those who were on treatment 
and or on follow up.   
 
 
Age also may seem to play an important role in fatigue, with the elderly expected to have 
more fatigue compared to younger group of patients. We looked at prevalence of fatigue in 
the various age groups, and we did not find any obvious difference (Table 6) 
 
 
Table 6 Prevalence of Fatigue in different age groups 
Age FAS > 21 FAS ≤ 21 
< 40 yrs 10 (83.3%) 2 (16.7%) 
40-49yrs 24 (75%) 8 (25%) 
50-59yrs 14 (63%) 8 (36.4%) 
>60 yrs 7 (77.8%) 2 (22.2%) 
 
 
We also looked to see if there is any difference in the prevalence of fatigue between males 
and females.  Our results are displayed in Table 7 as follows: 
Table 7 Prevalence of fatigue based on gender 
 FAS > 21 FAS ≤ 21 
Male  29 (70.7%) 12 (29.3%) 
Female 26 (76.5%) 8(23.5%) 
 
We found that female gender had slightly more prevalence in Fatigue compared to male 
gender 76.7% vs 70.7%, but it was not found to be statistically significant. 
 
 
We also looked at patients who were on steroids and the prevalence of fatigue in them.  It is 
shown in Table 8. 
 
Patients who were on treatment were found to have a lower prevalence of fatigue 
compared to patients who were not on treatment. 
 
On treatment FAS > 21 FAS ≤ 21 
Yes  25 (67.6%) 12 (32.4%) 
No  30 (80.9%) 8 (21.1%) 
Table 8 Prevalence of fatigue based on steroid treatment  
 
Table 9 shows the prevalence of fatigue in sarcoidosis patients who were being treated with 
steroids 
Steroids FAS > 21 FAS ≤ 21 
Yes 25 (67.6%) 12 (32.4%) 
No 6 (60%) 4 (40%) 
 
There was no significant difference in the level of fatigue in patients between those who 
were on steroids and those who were not on steroids. 
 
Analysis was done to look at the prevalence of fatigue in relation to duration of sarcoidosis 
since diagnosis. Following is a table which shows the prevalence according to their duration 
since diagnosis in old patients. 
 
 Table 10 showing prevalence of fatigue in patients against duration since diagnosis of 
Sarcoidosis 
Duration FAS > 21 FAS ≤ 21 
0-1 Month 
 
23 (85.2%) 4 (14.8%) 
1-6 months 3 (75%) 1 (25%) 
6-12 months 5 (71.4%) 2(28.6%) 
>12 months 24 (64.9%) 13 (35.1%) 
 
As the duration since diagnosis increased, the fatigue decreased..  In patients who are just 
diagnosed in their first month the prevalence is 85.2% and as the duration crosses 1 year the 
prevalence in that group of patients is only 64.9%. Although we did not find any statistical 
significance using the chi square test, we found a p value of 0.346 
 
Extra-pulmonary manifestations are common in Sarcoidosis and the prevalence of fatigue in 
those with other extra-pulmonary manifestation was also studied.  We looked at various 
extra-pulmonary manifestations and if any particular extra-pulmonary manifestation had 
more prevalence of fatigue compared to others.  Following is a table which depicts the 
same. 
 
 
 
  
Table 11 showing Extra-pulmonary manifestation of Sarcoidosis and prevalence of fatigue in 
each group 
Extra-pulmonary manifestation          Prevalence of fatigue 
 
 
Skin                                                73.3 
 
Eye                                                 70 
 
Liver                                               70 
 
Spleen                                            85.7 
 
Brain                                               66.7 
 
Parotid gland                                 100 
 
Bone, Joint, Muscle                        73 
 
ENT                                                   33 
 
Cardiac                                             100 
 
Calcium/renal                                   80 
 
 
 
 
There was only one patient each with parotid and cardiac manifestations and both of them 
had fatigue. Overall, there was high prevalence of fatigue in those with extra pulmonary 
symptoms. 
. 
We did logistic regression and calculated the odds of fatigue in variables such as presence of 
significant fatigue and whether age, sex and use of steroids were risk factors for 
development of fatigue.  Following is the table showing results from that: 
 
Table 12 Correlation of fatigue with various risk factors : 
Variable                    odds ratio(CI 95%)                  p value 
 
Steroids                         0.98(0.96-1.0)                      0.752 
 
Age                                 0.99(0.98-1.0)                      0.084 
 
Female sex                    1.09(0.83-1.4)                      0.478 
 
However, presumably because of the small numbers, this did not reach statistical 
significance.   
 
 
 
 
 
 
 
 
 
SECONDARY OBJECTIVE: EXTRA-PULMONARY 
MANIFESTATION 
 
Secondary objective of our study was to present the prevalence of Extra-pulmonary 
manifestations in the same cohort.  
Table 13 showing prevalence of various extra-pulmonary manifestations in Sarcoidosis  
Patients 
 
Extra-Pulmonary Manifestation                  Prevalence (%) 
 
1.Skin                                                                20% 
 
2. Eye                                                                26.6% 
 
3. Liver                                                              13%         
 
4. Spleen                                                            9.3% 
 
5. Brain                                                              4% 
 
6. Parotid gland                                                1.3% 
 
7. ENT                                                                 4% 
 
8. Heart                                                              1.3% 
 
9. Bone/Joint/Muscle                                      10.6% 
 
10. Calcium/ Kidney                                           6.6% 
                                                  
 
We found that 45 out of the 75 patients had extra-pulmonary involvement of some organ. 
This suggests that up to 60% of patients may have extra-pulmonary manifestation, if 
carefully looked for.  Since eye and skin are the most commonly involved organs in 
sarcoidosis, screening by specialists was done to identify presence of eye and skin 
manifestation.  We found a high prevalence of ophthalmological and dermatological 
manifestation, 26.6% and 20% respectively.  Next extra-pulmonary organ involvement was 
that of the liver – 13 % of patients had liver involvement, followed by bone, joint and muscle 
involvement in 10% of patients. 
Table 14 The frequency of extra-pulmonary involvement: 
No of EP                       Frequency 
 
0   30 (40%) 
 
 
1   25 (33.3%) 
 
 
2    14 (18.7) 
 
 
3      5 (6.7%) 
 
 
 
4       0 (0) 
 
 
5        1 (1.3%) 
 
 
 
Table 14 shows that patients can have up to 5 extra-pulmonary involvements 
simultaneously. 6.7% of them having 3 extra-pulmonary organ involvements.  
Around 18% of patients had 2 organs other than lungs involved due to Sarcoidosis. This data 
might be slightly skewed towards the higher limit as the study was performed in a tertiary 
referral centre, but definitely it reiterates the need to careful look out for extra-pulmonary 
manifestations in patients presenting with Sarcoidosis. 
 
Each organ has its characteristic manifestation in Sarcoidosis, our next section of results 
deals with each extra-pulmonary organ and respective prevalence of each type of 
manifestation in the sub group. 
Skin: 
 
Dermatological manifestations may vary from a non-specific lesion like erythema nodosum 
to a specific disfiguring lesion like Lupus pernio. 
Table 15 showing various Dermatological manifestations in Sarcoidosis patients 
 
Skin manifestation              Prevalence 
 
Lupus pernio                            2 (13.3%) 
 
Maculo papular                        9 (60%) 
 
Annular lesions                         1 (6.7%) 
 
Erythema nodosum                  3(20%) 
 
 
There were 15 patients with Dermatological manifestation, out of which the most 
frequently encountered was maculo-papular lesions – 60%, followed by Erythema nodosum 
and Lupus pernio and annular lesions in that order. We found relatively more maculo-
papular lesions compared to lupus pernio as described in the literature(67). 
 
EYE: 
 
Next most common organ to be involved as per literature is the eye.  But we found a higher 
prevalence of ophthalmological involvement than Dermatological manifestations.  20 out of 
the 75 patients had involvement of the eye.  Eighty percent of the patients presenting with 
uveitis and the rest with kerato-conjunctivitis.  We did not find other involvements of eye 
like cystoid macular edema. 
 
Table 16 Prevalence of Ophthalmological manifestation in Sarcoidosis patients 
Eye                           Prevalence 
Uveitis                               17 (85%) 
 
Kerato-conjunctivitis        3 (15%) 
 
 
LIVER: 
 
Next most commonly involved organ was liver. We found 10 among 75 patients who had 
liver manifestation.  There was equal prevalence of elevated liver enzymes i.e. 
transaminases and alkaline phosphatases and hepatomegaly.  There were 2 patients who 
had proved liver involvement with histopathology showing granulomatous inflammation.  
  
Table 17 showed liver involvement in Sarcoidosis patients 
Liver                              Prevalence 
 
Elevated enzymes               4 (40%) 
 
Hepatomegaly                     4 (40%) 
 
Liver granuloma                   2 (20%) 
 
  
SPLEEN: 
 
Splenic involvement was seen in 7 out of 75 patients.  All of them had splenomegaly as their 
manifestation and did not have any other spleen involvement. 
 
NERVOUS SYSTEM: 
 
Nervous system involvement can lead a higher morbidity compared to other extra-
pulmonary manifestations and hence their identification is important. We found 3 patients 
out of 75 to have cranial nerve palsy.  We did not find any other manifestation of neuro-
sarcoidosis in our patients. 
 
 
PAROTID AND SALIVARY GLAND: 
 
Parotid and Salivary gland involvement is another commonly reported involvement in 
Sarcoidosis, but we did not find that to be true in our population. We had only one patient 
who had parotid involvement in the form of Parotitis. 
 
ENT: 
 
Ear, Nose and Throat can also be involved in patients with Sarcoidosis.  Commonest 
manifestation we found was hearing loss which can be attributable to Sarcoidosis. It was 
seen in 3 patients out of 75.  We did not find any other manifestation of ear, nose or throat. 
 
HEART: 
 
Cardiac manifestations can also be seen in Sarcoidosis and it is most commonly found in 
Japanese population.  We found only 1 patient to have Cardiac involvement in the form of 
conduction block.  We did not have patients with any other manifestations. 
 
BONE / MUSCLE / JOINT: 
 
Involvement of bone, muscle and joint can be in the form of arthritis, arthralgia, myopathy. 
We found prevalence of this to be high with 8 out of 75 patients having Bone, Muscle and 
Joint involvement.  
Most of the patients had arthralgia as their primary manifestation.  Interestingly, few of 
these patients presented in the Rheumatology department with arthralgia as their primary 
symptom.   
 
 
 
 
Table 18 Prevalence of Bone/ Joint/Muscle involvement in Sarcoidosis patients 
Bone/Joint/Muscle         Prevalence 
 
Arthralgia                            7 (87.5%) 
 
Arthritis                                1 (12.5%) 
 
Others                                   0 
 
 
 
KIDNEY / CALCIUM (HYPERCALCEMIA, 
HYPERCALCIURIA): 
 
Patients may have involvement of the kidneys even present with renal failure. There were 
none with renal failure in our cohort. Hypercalciuria and Hypercalcemia which was seen to 
be 2 and 3 respectively in our cohort of Sarcoidosis patients. 
 
 
  
Table 19 showing prevalence of Calcium / Renal involvement in Sarcoidosis patients. 
Calcium / Renal              Prevalence 
 
Hypercalcemia                   3 (60%) 
 
Hypercalciuria                    2 (40%) 
 
Others                                  0 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION: 
 
Pulmonary Sarcoidosis is a multi-system, granulomatous disorder affecting the lung most 
commonly, followed by other organs like Skin, Eye, Liver, and Brain.  Sarcoidosis can virtually 
affect any organ.  It is diagnosed on the basis of a concordant clinical picture, radiological 
correlation and histo-pathological diagnosis. 
 
Our aim was to look at a symptom which is usually neglected in clinical practice.  Fatigue 
synonymously used with excessive tiredness, malaise, lethargy and depression is one of the 
common symptoms which a patient experiences when he suffers with Sarcoidosis.  This 
symptom is neglected and when not addressed leads to poor quality of life in patients.  
There have been only few trials looking at the prevalence on fatigue in patients with 
Sarcoidosis.  There is no approved treatment for fatigue in patients who suffer with 
Sarcoidosis.  Drugs which fall into the category of neuro-stimulants like methylphenidate,   
D-Methylphenidate and Armodafinil have been used with little effect.  There are no 
guidelines to diagnose and / or treat fatigue in Sarcoidosis patients.  
 
In our study we tried to look at the prevalence of Fatigue as a symptom in patients with 
Sarcoidosis.  This study was planned to reiterate the importance of fatigue and the burden 
of the symptom in Sarcoidosis patients.  The tool which was used to study fatigue in them is 
the Fatigue Assessment Scale which has been validated for assessing fatigue in patients with 
Sarcoidosis.  It has 10 simple questions with a 5 point likert scale of never to always.   
Maximum score is 50 and minimum score is 10.  Patients whose score is 22 or above is 
considered to have fatigue.  It should be considered as an important symptom in these 
patients.   
 
We included 75 patients in our study to assess for fatigue.  All of them had Pulmonary 
Sarcoidosis.  Histo-pathological diagnosis of Sarcoidosis was present in all of them.  Patients 
who were on treatment and those who were treatment naïve were also included, since the 
literature review done did not show any difference in fatigue experienced between these 2 
groups.  After obtaining informed consent in patients own language, FAS score was filled 
and recorded in the pro-forma for analysis. 
 
We analyzed the data for fatigue in all these patients and multiple variables were studied.  
The primary objective of the study was to present the prevalence of fatigue in patients with 
Sarcoidosis.  Prevalence of fatigue in our patients was very high at 73.3%.  We carefully 
excluded confounders for fatigue like Anemia, Hypothyroidism, Malignancy and 
Tuberculosis.  Patients whose clinical status could not be differentiated between Sarcoidosis 
and Tuberculosis who were on therapy for both were also excluded.  Patients on steroids 
may have fatigue secondary to the drug intake and myopathy associated with it.  We 
decided to capture data of dose and duration of steroids which patients have been on since 
diagnosis and analyze it to see if it was a risk factor for increased fatigue in patients with 
Sarcoidosis using logistic regression.  We also looked at duration since the diagnosis of 
Sarcoidosis, if it had any impact on fatigue by comparing the groups who were just started 
on treatment and those who were on steroids for at least an year.   
 
Prevalence of fatigue which we found was very high in patients who are diagnosed with 
Sarcoidosis in our institution. 73% of the population with sarcoidosis experience fatigue as a 
major symptom.  It was seen that patients who were on treatment for Sarcoidosis had 
slightly lesser prevalence of fatigue compared to those who were diagnosed new, 
suggesting a possibility of fatigue showing minimal improvement with treatment of 
sarcoidosis.  To support the same , patients who were diagnosed 12 months or more and 
have been on treatment showed lesser prevalence of fatigue compared to those who were 
treatment naïve or those who were diagnosed within 1 month period.   We also looked at 
patients fatigue in comparison with the dose of steroids they were on, that also did not 
show any significant difference in the four groups which we studies.  We divided patients on 
steroids into 4 groups depending on the dose of steroids they were on, starting from 0-
10mg on one group, followed by 11-19mg in the next, 20-29 in the next group,  
 
 
 
 
 
 
 
 
 
CONCLUSION: 
 
We studied patients with sarcoidosis which is a rare disorder.  We included 75 patients in 
our study and assessed the prevalence of fatigue and other extra-pulmonary manifestations.  
Prevalence of sarcoidosis is very high, we found the prevalence to be 73.3%, which is in 
accordance with the studies mentioned in the review of literature.  It may be as high as 
87.5% in newly diagnosed patients.  Since we had patients who were on follow up and 
patients who were treatment naïve, we assessed the difference between both the groups.  
In follow up patients prevalence was 66% compared to 87% in the newly diagnosed group).  
There was no significant difference statistically in age or female sex – odd’s ratio of 0.99 and 
1.09 respectively in the study, which could be because of the small sample size.  A larger 
study is required to analyse risk factors like age and sex on fatigue in sarcoidosis. 
Mainstay of treatment for sarcoidosis is steroids.  Steroids may induce myopathy and cause 
fatigue.  We found patients on steroids had 9% higher risk of having fatigue, but statistically 
it was not found to be significant (odd’s ratio; 0.98, p value; 0.752).   
Our study reiterates the importance of fatigue as a predominant symptom in patients with 
sarcoidosis which may be ignored in the clinical setting.  Further studies are required to 
identify therapies which may help patients in treating this symptom.  Treatment of fatigue 
will improve quality of life of the patient which is one of the primary goals of treating 
patients with sarcoidosis. 
We also assessed the same cohort of patients to identify the presence of extra-pulmonary 
manifestations in them.  We strongly recommend minimal initial investigations in a patient 
with suspicion or diagnosis of sarcoidosis, to assess for extra-pulmonary manifestation.  
These investigations are as follows: 
 Complete blood count 
 Urea and creatinine 
 Liver function tests 
 Serum and urinary calcium(24 hour) 
 ECG 
 Eye and Skin screening 
 Organ specific history and examination 
Above mentioned screening tests were done in all 75 patients and we found the presence of 
extra-pulmonary manifestations in 45 of them.  We observed highest prevalence in Eye and 
Skin with 26% and 20% respectively.  Other organs involved in decreasing order of 
prevalence were Liver (13%), Bone/Joint/Muscle (10.6%), Spleen (9.3%), Calcium/Kidney 
(6.6%), Brain (4%), ENT (4%), Heart (1.3%), and Parotid gland (1.3%). 
A larger study is required to validate a screening questionnaire for patients with sarcoidosis. 
 
 
 
 
 
 
BIBLIOGRAPHY: 
1.  Criado E, Sánchez M, Ramírez J, Arguis P, de Caralt TM, Perea RJ, et al. Pulmonary sarcoidosis: 
typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiogr 
Rev Publ Radiol Soc N Am Inc. 2010 Oct;30(6):1567–86.  
2.  Sharma SK, Mohan A. Sarcoidosis in India: not so rare. J Indian Acad Clin Med. 2004;5(1):12–21.  
3.  Rosen Y. Pathology of Sarcoidosis. Semin Respir Crit Care Med. 2007 Feb;28(1):036–52.  
4.  Mukhopadhyay S, Gal AA. Granulomatous lung disease: an approach to the differential 
diagnosis. Arch Pathol Lab Med. 2010 May;134(5):667–90.  
5.  FSR-Physicians-Protocol1.pdf [Internet]. [cited 2013 Oct 21]. Available from: 
http://www.stopsarcoidosis.org/wp-content/uploads/2013/03/FSR-Physicians-Protocol1.pdf 
6.  Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007 Nov 22;357(21):2153–65.  
7.  Sarcoidosis. N Engl J Med. 2008 Mar 27;358(13):1402–5.  
8.  Sarcoidosis: A Primary Care Review - American Family Physician [Internet]. [cited 2013 Oct 21]. 
Available from: http://www.aafp.org/afp/1998/1201/p2041.html 
9.  Joshi JM, Saxena S. Sarcoidosis in India. Skin. 2012;11(34):2–20.  
10.  Gupta SK, Mitra K, Chatterjee S, Chakravarty SC. Sarcoidosis in India. Br J Dis Chest. 1985 
Jul;79(3):275–83.  
11.  Drent M, Lower EE, Vries JD. Sarcoidosis-associated fatigue. Eur Respir J. 2012 Jul 1;40(1):255–
63.  
12.  Aaronson LS, Teel CS, Cassmeyer V, Neuberger GB, Pallikkathayil L, Pierce J, et al. Defining and 
Measuring Fatigue. Image J Nurs Sch. 1999 Mar 1;31(1):45–50.  
13.  Drent M, Lower EE, Vries JD. Sarcoidosis-associated fatigue. Eur Respir J. 2012 Jul 1;40(1):255–
63.  
14.  Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. FAtigue is associated with quality of life 
in sarcoidosis patients*. Chest. 2006 Oct 1;130(4):989–94.  
15.  Bush A, Carlsen K-H, Zach M, European Respiratory Society. Growing up with lung disease: the 
lung in transition to adult life. Sheffield: European Respiratory Society Journals; 2002.  
16.  De Kleijn WP, De Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: 
a systematic review: Curr Opin Pulm Med. 2009 Sep;15(5):499–506.  
17.  Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012 Jul 
1;40(1):255–63.  
18.  De Vries J, Drent M. Quality of Life and Health Status in Sarcoidosis: A Review. Semin Respir 
Crit Care Med. 2007 Feb;28(1):121–7.  
19.  Fatigue in sarcoidosis: a systematic review. [Curr Opin Pulm Med. 2009] - PubMed - NCBI 
[Internet]. [cited 2013 Oct 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19458531 
20.  Marcellis RGJ, Lenssen AF, Elfferich MDP, Vries JD, Kassim S, Foerster K, et al. Exercise capacity, 
muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011 Sep 1;38(3):628–34.  
21.  Sharma OP. Fatigue and sarcoidosis. Eur Respir J. 1999;13(4):713–4.  
22.  De Kleijn WPE, Elfferich MDP, De Vries J, Jonker GJ, Lower EE, Baughman RP, et al. Fatigue in 
sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG 
World Assoc Sarcoidosis Granulomatous Disord. 2009 Jul;26(2):92–7.  
23.  Cottin V, Müller-Quernheim J. Sarcoidosis from bench to bedside: a state-of-the-art series for 
the clinician. Eur Respir J. 2012 Jul 1;40(1):14–6.  
24.  Vucinic V, Stojkovic M, Milenkovic B, Videnovic-Ivanov J, Skodric-Trifunovic V, Zugic V, et al. 
Fatigue in sarcoidosis: Detection and treatment. Srp Arh Celok Lek. 2012;140(1-2):104–9.  
25.  Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson MA. Differences in 
symptom severity and health status impairment between patients with pulmonary and 
pulmonary plus extrapulmonary sarcoidosis. Respir Med. 2008 Nov;102(11):1636–42.  
26.  Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012 Jul 
1;40(1):255–63.  
27.  ******* CIS20R ******* - CIS.pdf [Internet]. [cited 2014 Sep 16]. Available from: 
http://arni.uk.com/pdf/CIS.pdf 
28.  Korenromp IHE, Heijnen CJ, Vogels OJM, van den Bosch JMM, Grutters JC. Characterization of 
chronic fatigue in patients with sarcoidosis in clinical remission. Chest. 2011 Aug;140(2):441–7.  
29.  De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue 
Assessment Scale (FAS). Br J Health Psychol. 2004 Sep;9(Pt 3):279–91.  
30.  Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for Sarcoidosis-Associated 
Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial. J Pain Symptom Manage. 2013 
Feb;45(2):159–69.  
31.  Lower EE. Double-Blind, Randomized Trial of Dexmethylphenidate Hydrochloride for the 
Treatment of Sarcoidosis-Associated Fatigue&lt;xref 
rid=“AFF1”&gt;&lt;sup&gt;*&lt;/sup&gt;&lt;/xref&gt; CHEST J. 2008 May 1;133(5):1189.  
32.  Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) 
psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995 
Apr;39(3):315–25.  
33.  Hinz A, Fleischer M, Brähler E, Wirtz H, Bosse-Henck A. Fatigue in patients with sarcoidosis, 
compared with the general population. Gen Hosp Psychiatry. 2011 Sep;33(5):462–8.  
34.  Fleischer M, Hinz A, Brähler E, Wirtz H, Bosse-Henck A. Factors Associated With Fatigue in 
Sarcoidosis. Respir Care. 2014 Jul 1;59(7):1086–94.  
35.  Kalkanis A, Yucel RM, Judson MA. The internal consistency of PRO fatigue instruments in 
sarcoidosis: superiority of the PFI over the FAS. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG 
World Assoc Sarcoidosis Granulomatous Disord. 2013 Mar;30(1):60–4.  
36.  Marcellis RGJ, Lenssen AF, Elfferich MDP, De Vries J, Kassim S, Foerster K, et al. Exercise 
capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011 Mar 24;38(3):628–34.  
37.  Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday Cognitive 
Failure in Sarcoidosis: The Prevalence and the Effect of Anti-TNF-alpha Treatment. Respiration. 
2010;80(3):212–9.  
38.  Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue 
measure: The Fatigue Assessment Scale. J Psychosom Res. 2003 Apr;54(4):345–52.  
39.  Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in 
sarcoidosis. Chest. 2007 Jul;132(1):207–13.  
40.  De Kleijn WPE, De Vries J, Wijnen PAHM, Drent M. Minimal (clinically) important differences 
for the Fatigue Assessment Scale in sarcoidosis. Respir Med. 2011 Sep;105(9):1388–95.  
41.  De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue 
and clinical parameters in acute pulmonary sarcoidosis. [cited 2014 Sep 23]; Available from: 
http://www.ildcare.eu/Downloads/proefschriften/proefschriften_2004/Thesis_S._Rothkrantz_
-_2004_-_Chapter_06.pdf 
42.  Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012 Jul 
1;40(1):255–63.  
43.  Microsoft Word - ERJ-00025-
2012_Revision_Review_Sarcoidosis_associated_fatigue_ERJ_Marked_Copy - 
09031936.00002512.full.pdf [Internet]. [cited 2014 Sep 15]. Available from: 
http://erj.ersjournals.com/content/early/2012/03/22/09031936.00002512.full.pdf 
44.  0370-81791202104V.pdf [Internet]. [cited 2014 Sep 16]. Available from: 
http://www.doiserbia.nb.rs/img/doi/0370-8179/2012/0370-81791202104V.pdf 
45.  Costabel U. Skeletal muscle weakness, fatigue and sarcoidosis. Thorax. 2005 Jan 1;60(1):1–2.  
46.  Heij L, Dahan A, Hoitsma E. Sarcoidosis and Pain Caused by Small-Fiber Neuropathy. Pain Res 
Treat. 2012 Dec 5;2012:e256024.  
47.  - hoitsma_-_2005_-_chapter_05.pdf [Internet]. [cited 2014 Sep 18]. Available from: 
http://www.ildcare.eu/downloads/proefschriften/proefschriften_2005/hoitsma_-_2005_-
_chapter_05.pdf 
48.  Drent M, Verbraecken J, van der Grinten C, Wouters E. Fatigue associated with obstructive 
sleep apnea in a patient with sarcoidosis. Respir Int Rev Thorac Dis. 2000;67(3):337–40.  
49.  Turner GA, Lower EE, Corser BC, Gunther KL, Baughman RP. Sleep apnea in sarcoidosis. 
Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG World Assoc Sarcoidosis Granulomatous Disord. 
1997 Mar;14(1):61–4.  
50.  Kleijn_fatigue_16-05-2012.pdf [Internet]. [cited 2014 Sep 15]. Available from: 
https://pure.uvt.nl/portal/files/1428538/Kleijn_fatigue_16-05-2012.pdf 
51.  Magnusson AE, Nias DK, White PD. Is perfectionism associated with fatigue? J Psychosom Res. 
1996 Oct;41(4):377–83.  
52.  Sharma OP, Mihailovic-Vucinic V. Lesions of Sarcoidosis. JP Medical Ltd; 2014. 200 p.  
53.  Marcellis RGJ, Lenssen AF, Elfferich MDP, Vries JD, Kassim S, Foerster K, et al. Exercise capacity, 
muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011 Sep 1;38(3):628–34.  
54.  De Kleijn WPE, Drent M, Vermunt JK, Shigemitsu H, De Vries J. Types of fatigue in sarcoidosis 
patients. J Psychosom Res. 2011 Dec;71(6):416–22.  
55.  Erckens RJ, Mostard RLM, Wijnen P a. HM, Schouten JS, Drent M. Adalimumab successful in 
sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp 
Ophthalmol Albrecht Von Graefes Arch Für Klin Exp Ophthalmol. 2012 May;250(5):713–20.  
56.  Microsoft Word - Fatigue from sarcoidosis treat the cause.doc - 
Fatigue_from_sarcoidosis_treat_the_cause.pdf [Internet]. [cited 2014 Sep 16]. Available from: 
http://www.ildcare.eu/Downloads/nieuws/Fatigue_from_sarcoidosis_treat_the_cause.pdf 
57.  Okumus G, Musellim B, Cetinkaya E, Turker H, Uzaslan E, Yenturk E, et al. Extrapulmonary 
involvement in patients with sarcoidosis in Turkey: Extrapulmonary sarcoidosis in Turkey. 
Respirology. 2011 Apr;16(3):446–50.  
58.  Extrapulmonary Sarcoidosis.pdf [Internet]. [cited 2013 Oct 21]. Available from: 
http://pneumonologia.gr/articlefiles/Extrapulmonary%20Sarcoidosis.pdf 
59.  Chapter 10 Skin manifestations in sarcoidosis.pdf [Internet]. [cited 2014 Sep 18]. Available 
from: 
http://www.ildcare.eu/Downloads/artseninfo/Sarcoidosis/Chapter%2010%20Skin%20manifest
ations%20in%20sarcoidosis.pdf 
60.  Yanardağ H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the 
features in 170 patients. Respir Med. 2003 Aug;97(8):978–82.  
61.  Cutaneous Sarcoidosis: A Dermatologic Masquerader - American Family Physician [Internet]. 
[cited 2014 Sep 18]. Available from: http://www.aafp.org/afp/2002/0415/p1581.html 
62.  Abu-Hilal M, Krotva J, Chichierchio L, Obeidat N, Madanat M. Dermatologic aspects and 
cutaneous manifestations of sarcoidosis. G Ital Dermatol E Venereol Organo Uff Soc Ital 
Dermatol E Sifilogr. 2010 Dec;145(6):733–45.  
63.  Symptoms of Sarcoidosis [Internet]. [cited 2014 Sep 18]. Available from: 
https://chronicillnessrecovery.org/index.php?option=com_content&view=article&id=190 
64.  Grunewald J, Eklund A. Löfgren’s Syndrome. Am J Respir Crit Care Med. 2009 Feb 
15;179(4):307–12.  
65.  Mañá J, Marcoval J, Graells J, Salazar A, Peyrí J, Pujol R. Cutaneous involvement in sarcoidosis: 
Relationship to systemic disease. Arch Dermatol. 1997 Jul 1;133(7):882–8.  
66.  Reddy RR, Shashi Kumar BM, Harish MR. CUTANEOUS SARCOIDOSIS - A GREAT MASQUERADER: 
A REPORT OF THREE INTERESTING CASES. Indian J Dermatol. 2011;56(5):568–72.  
67.  Yanardag H, Tetikkurt C, Bilir M, Demirci S, Iscimen A. Diagnosis of cutaneous sarcoidosis; 
clinical and the prognostic significance of skin lesions. Multidiscip Respir Med. 2013 Mar 
22;8(1):26.  
68.  Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, et al. Efficacy of infliximab in 
extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008 Jun;31(6):1189–
96.  
69.  Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al. Infliximab therapy 
in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 
2006 Oct 1;174(7):795–802.  
70.  ocular_sarcoidosis.pdf [Internet]. [cited 2013 Oct 21]. Available from: 
http://www.uveitis.org/docs/dm/ocular_sarcoidosis.pdf 
71.  Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000 Jan 1;84(1):110–6.  
72.  - 234.full.pdf [Internet]. [cited 2014 Sep 18]. Available from: 
http://aje.oxfordjournals.org/content/145/3/234.full.pdf 
73.  Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000 Jan 1;84(1):110–6.  
74.  ocular sarcoid..pdf [Internet]. [cited 2014 Sep 18]. Available from: 
http://www.med.unc.edu/tarc/events/event-files/ocular%20sarcoid..pdf 
75.  zotero://attachment/406/ [Internet]. [cited 2014 Sep 19]. Available from: 
zotero://attachment/406/ 
76.  Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H. Defining organ involvement in 
sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control 
Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG World Assoc 
Sarcoidosis Granulomatous Disord. 1999 Mar;16(1):75–86.  
77.  Herbort CP, Rao NA, Mochizuki M, members of Scientific Committee of First International 
Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: 
results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol 
Inflamm. 2009 Jun;17(3):160–9.  
78.  zotero://attachment/416/ [Internet]. [cited 2014 Sep 19]. Available from: 
zotero://attachment/416/ 
79.  Ayyala US, Padilla ML. Diagnosis and treatment of hepatic sarcoidosis. Curr Treat Options 
Gastroenterol. 2006;9(6):475–83.  
80.  getpdf.php [Internet]. [cited 2014 Sep 19]. Available from: 
http://njmonline.nl/getpdf.php?t=a&id=10000876 
81.  Hepatic Sarcoidosis: Clinicopathologic Features in 100 Patie... : The American Journal of 
Surgical Pathology [Internet]. [cited 2014 Sep 19]. Available from: 
http://journals.lww.com/ajsp/abstract/1993/12000/hepatic_sarcoidosis__clinicopathologic_fe
atures_in.9.aspx 
82.  Warshauer DM, Lee JKT. Imaging Manifestations of Abdominal Sarcoidosis. Am J Roentgenol. 
2004 Jan 1;182(1):15–28.  
83.  Patel I, Ismajli M, Steuer A. Sarcoidosis Presenting as Massive Splenic Infarction. Case Rep 
Rheumatol. 2012 Jul 30;2012:e834758.  
84.  zotero://attachment/83/ [Internet]. [cited 2014 Aug 16]. Available from: 
zotero://attachment/83/ 
85.  Selroos O. Sarcoidosis of the Spleen. Acta Med Scand. 1976 Jan 12;200(1-6):337–40.  
86.  DELANEY P. Neurologic Manifestations in SarcoidosisReview of the Literature, with a Report of 
23 Cases. Ann Intern Med. 1977 Sep 1;87(3):336–45.  
87.  Neurological complications of sarcoidosis : Current Opinion in Neurology [Internet]. [cited 2014 
Sep 19]. Available from: http://journals.lww.com/co-
neurology/Fulltext/2004/06000/Neurological_complications_of_sarcoidosis.13.aspx 
88.  Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. 
Arch Neurol. 1985 Sep;42(9):909–17.  
89.  Gullapalli D, Phillips LH. Neurologic manifestations of sarcoidosis. Neurol Clin. 2002 
Feb;20(1):59–83, vi.  
90.  Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous 
system sarcoidosis—diagnosis and management. QJM. 1999 Feb 1;92(2):103–17.  
91.  Christoforidis GA, Spickler EM, Recio MV, Mehta BM. MR of CNS Sarcoidosis: Correlation of 
Imaging Features to Clinical Symptoms and Response to Treatment. Am J Neuroradiol. 1999 
Apr 1;20(4):655–69.  
92.  Lower EE, Broderick JP, Brott TG, Baughman RP. DIagnosis and management of neurological 
sarcoidosis. Arch Intern Med. 1997 Sep 8;157(16):1864–8.  
93.  James DG, Sharma OP. Parotid gland sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis Off J 
WASOG World Assoc Sarcoidosis Granulomatous Disord. 2000 Mar;17(1):27–32.  
94.  Fatahzadeh M, Rinaggio J. Diagnosis of systemic sarcoidosis prompted by orofacial 
manifestations: a review of the literature. J Am Dent Assoc 1939. 2006 Jan;137(1):54–60.  
95.  Walter C, Schwarting A, Hansen T, Weibrich G. [Heerfordt’s syndrome -- a rare initial 
manifestation of sarcoidosis]. Mund- Kiefer- Gesichtschirurgie MKG. 2005 Jan;9(1):43–7.  
96.  Harvey J, Catoggio L, Gallagher PJ, Maddison PJ. Salivary gland biopsy in sarcoidosis. 
Sarcoidosis. 1989 Mar;6(1):47–50.  
97.  Beeley JA, Chisholm DM. Sarcoidosis with salivary gland involvement: biochemical studies on 
parotid saliva. J Lab Clin Med. 1976 Aug;88(2):276–81.  
98.  Çakmak SK, Gönül M, Gül Ü, Gündüz H, Han Ö, Kulaçoğlu S. Sarcoidosis involving the lacrimal, 
submandibular, and parotid glands with panda sign. Dermatol Online J [Internet]. 2009 Mar 1 
[cited 2014 Sep 20];15(3). Available from: https://escholarship.org/uc/item/80j4r407 
99.  Browne PM, Sharma OP, Salkin D. BOne marrow sarcoidosis. JAMA. 1978 Dec 8;240(24):2654–
5.  
100.  Yanardağ H, Pamuk GE, Karayel T, Demirci S. Bone marrow involvement in sarcoidosis: an 
analysis of 50 bone marrow samples. Haematologia (Budap). 2002;32(4):419–25.  
101.  Mostard RL, Prompers L, Weijers RE, van Kroonenburgh MJ, Wijnen PA, Geusens PP, et al. F-18 
FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl 
Med. 2012 Jan;37(1):21–5.  
102.  Prompers L, Mostard R, Weyers R, Drent M, Voo S, van Kroonenburgh M. Assessing bone 
(marrow) involvement in sarcoidosis using F18-FDG PET/CT. Soc Nucl Med Annu Meet Abstr. 
2011 May 1;52(1_MeetingAbstracts):513.  
103.  Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis. 1988 
Mar;5(1):51–5.  
104.  Milton CM. Sarcoidosis in ENT practice. Clin Otolaryngol Allied Sci. 1985 Dec;10(6):351–5.  
105.  20060502_Sinonasal_Sarcoidosis.pdf [Internet]. [cited 2014 Sep 20]. Available from: 
http://www.pneumonologia.gr/articlefiles/20060502_Sinonasal_Sarcoidosis.pdf 
106.  CAMA E, SANTARELLI R, MUZZI E, INCHES I, CURTOLO S, DI PAOLA F, et al. Sudden hearing loss 
in sarcoidosis: otoneurological study and neuroradiological correlates. Acta Otorhinolaryngol 
Ital. 2011 Aug;31(4):235–8.  
107.  Internet Scientific Publications [Internet]. [cited 2014 Sep 20]. Available from: 
http://ispub.com/IJORL/13/1/12797 
108.  Pierre-Louis B, Prasad A, Frishman WH. Cardiac manifestations of sarcoidosis and therapeutic 
options. Cardiol Rev. 2009 Aug;17(4):153–8.  
109.  Chapter 9 Cardiac involvement in sarcoidosis.pdf [Internet]. [cited 2014 Sep 20]. Available 
from: 
http://ildcare.eu/Downloads/artseninfo/Sarcoidosis/Chapter%209%20Cardiac%20involvement
%20in%20sarcoidosis.pdf 
110.  Sekhri V, Sanal S, DeLorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: a comprehensive 
review. Arch Med Sci AMS. 2011 Aug;7(4):546–54.  
111.  Diagnosis and Management of Cardiac Sarcoidosis - cardiac_sarcoidosis.pdf [Internet]. [cited 
2013 Oct 21]. Available from: http://www.sarcoidosisonlinesites.com/cardiac_sarcoidosis.pdf 
112.  Koyama T, Ueda H, Togashi K, Umeoka S, Kataoka M, Nagai S. Radiologic Manifestations of 
Sarcoidosis in Various Organs1. RadioGraphics. 2004 Jan;24(1):87–104.  
113.  Chapter 13 Sarcoidosis joint muscle and bone.pdf [Internet]. [cited 2013 Oct 21]. Available 
from: 
http://www.ildcare.eu/Downloads/artseninfo/Sarcoidosis/Chapter%2013%20Sarcoidosis%20jo
int%20muscle%20and%20bone.pdf 
114.  Zisman DA, Shorr AF, Lynch JP. Sarcoidosis involving the musculoskeletal system. Semin Respir 
Crit Care Med. 2002 Dec;23(6):555–70.  
115.  Moore SL, Teirstein AE. Musculoskeletal Sarcoidosis: Spectrum of Appearances at MR 
Imaging1. RadioGraphics. 2003 Nov;23(6):1389–99.  
116.  Conron M, Young C, Beynon HLC. Calcium metabolism in sarcoidosis and its clinical 
implications. Rheumatology. 2000 Jul 1;39(7):707–13.  
117.  Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax. 1998 
May 1;53(5):425–9.  
118.  Fowler A, Dargan P, Jones A. Puzzling hypercalcaemia: sarcoidosis without lung involvement. J 
R Soc Med. 2005 Feb;98(2):60–1.  
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE: 
 
Proforma: 
 
1. Serial Number: 
 
2. Name: 
 
3. Hospital number: 
 
4. Age: 
 
5. Sex: Male/Female 
 
6. Marital status: Married/ Unmarried 
 
7. Profession: 
 
8. Any exclusion criteria met:   Yes / No 
 
9. Informed consent obtained:    Yes / No 
 
10. Kindly answer Yes/No to the following questions: 
 
a. Diagnosed with Pulmonary Sarcoidosis  :  Yes/ No 
 
                                                Histopathological Diagnosis: Yes / No 
                                                          
                                                New / Old patient:    
                                                 
                                                Duration since diagnosis:  
 
 
b. On treatment for Sarcoidosis  :  Yes / No – If Yes, answer 
following: 
1. On steroids: 
2. Current dose of steroids:  
3. Duration of treatment: 
4. Other treatment/Duration: 
 
 
 
c. If Subjective symptom of fatigue present: Yes / No 
                   
          Fatigue assessment score completed: Yes / No 
FAS Score:  
 
d. Any skin manifestation : Yes / No – If Yes, Circle: Lupus pernio/ 
Maculopapular lesions/Annular lesion/Erythema 
nodosum/Others 
 
e. Ocular manifestation: Yes / No – If Yes, Circle: Anterior 
uveitis/Posterior uveitis/Retinal 
Vasculitis/Kerataconjunctivitis/Others  
 
f. Liver involvement: Yes / No – If Yes, Circle: Elevated Liver 
enzymes/ Hepatomegaly/ granulomas In liver biopsy/Others 
 
g. Spleen involevement: Yes / No – If Yes, Circle: Splenomegaly / 
Splenic infarcts / Others 
 
 
h. Brain involvement :Yes / No – If Yes, Circle: cranial-nerve 
palsies/headache/ataxia/cognitive dysfunction/ 
seizures/others 
 
i. Parotid/salivary gland involvement: Yes / No  
 
 
j. Bone marrow involvement: Yes / No – If Yes, Circle: Anemia, 
Leucopenia/Thrombocytopenia/ Bone marrow biopsy with 
granulomas/Others 
 
 
k. ENT Involvement: Yes / No – If Yes, Circle: Hearing Loss/ Nasal 
obstruction/Rhinorrhea 
 
 
l. Cardiac manifestation: Yes / No – If Yes, Circle: 
Arrhythmias/Conduction blocks/ Others  
 
 
m. Bone/Joint/Muscle involvement: Yes / No – If Yes, Circle: 
Arthralgia/Arthritis/Myopathy/Others  
 
 
n. Calcium/Renal involvement: Yes / No – If Yes, Circle: 
Hypercalcemia /Hypercalciuria/Others 
 
 
 Information sheet: 
 
Study title 
To calculate the number of people suffering with the symptom of fatigue in all patients 
diagnosed to have a disease called as Sarcoidosis . 
 
Invitation paragraph 
'You are being invited to take part in a research study. Before you decide whether or not to 
take part, it is important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully'. 
 
What is the purpose of the study? 
  It has been seen that the symptom of Fatigue is incompletely understood and treated, 
hence this study will try to reinstate the importance of fatigue in patients suffering with 
Sarcoidosis. And will also capture the prevalence of other organ involvement in Sarcoidosis. 
 
Why have I been invited to participate? 
 You have been invited to participate in the study since you have been diagnosed with Sarcoidosis 
and that your valuable time in filling the questionnaire will help physicians worldwide to understand 
the importance of fatigue. A minimum of 50 patients are required for us to complete the study, 
therefore we will require another 49 patients like you with the same diagnosis will be enrolled. 
 
Do I have to take part? 
'It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason'. 
 
What will happen to me if I take part? 
You will be asked to fill in a questionnaire with 10 simple questions , where you will be 
asked to grade from 1 to 5 for all the questions, at the end a score will be calculated to 
assess if you are experiencing symptoms of fatigue. It will take around 10 to 15min of your 
valuable time. Your blood and other results will be seen to look for oragns other than lung 
involvement in you for analysing the final data for the study. All data collected will be strictly 
confidential and it will be stored and analysed for research purposes in the coming time. All 
details will be stored as an electronic and paper copy. You don’t have to pay anything to 
take part in the study. 
 
What should I do if I want to take part? 
You will have to sign the consent form attached to this information sheet and fill in the 
Fatigue Assesment Scale questionnaire which will be given to you as described earlier. 
 
What will happen to the results of the research study? 
The results of this study will be analysed and submitted as a part of my Thesis and if 
approved will be published for the interest of the medical fraternity. There are no added 
risks associated with this study.  You may have to spend approximately 5-15 min extra to 
participate in this study as explained earlier. 
 
Your details will be kept confidential and will not be disclosed with any one who is not 
associated with the study. Your participation in this study is entirely voluntary and you are 
also free to decide to withdraw permission to participate in this study. If you do so, this will 
not affect your usual treatment at this hospital in any way.  
 
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission, should 
you decide to participate in this study. 
 
 
Who is organising and funding the research? 
This study is being organised by the Department of Pulmonary Medicine, Christian Medical 
College, Vellore and funded by the Christian Medical College, Vellore. 
 
Who has reviewed the study? 
This study has been reviewed by the Institutional Review Board, Christian Medical College, 
Vellore. 
 
Contact for Further Information 
You are free to contact the principal investigator of the study for any doubts at the following 
contact information provided.. 
 
 
We thank you for taking time to read the information sheet. 
 
Date: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consent From: 
 
CONSENT FORM 
 
 
Full title of Project: To Calculate the Prevalence of Fatigue in patients diagnosed with 
Sarcoidosis with the help of Fatigue Assessment Scale and to present the observed 
prevalence of other extra-pulmonary manifestations . 
 
Name, position and contact address of Researcher: Dr.Immanuel Subash.G, PG registrar, 
CMC Vellore, Tamil Nadu 
 
Subject’s Initials: _________ Subject’s Name: _________________________________ 
Date of Birth / Age:_______ 
 
  Please tick box(subject) 
(i) I confirm that I have read and understood the 
information sheet for the above study and have had 
the opportunity to ask questions.  
 
          
           [               ] 
(ii) I understand that my participation in the study is 
voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical 
care or legal rights being affected.  
 
            
 
            [                ] 
(iii) I understand that the Ethics Committee and the 
regulatory authorities will not need my permission 
to look at my health records both in respect of the 
current study and any further research that may be 
conducted in relation to it, even if I withdraw from 
the trial. I agree to this access. However, I 
understand that my identity will not be revealed in 
any information released to third parties or 
published.  
 
                         
 
 
 
           [                ] 
(iv) I agree not to restrict the use of any data or results 
that arise from this study provided such a use is only 
for scientific purpose(s)  
 
           
           [                ] 
(v) I agree to take part in the above study              [                ] 
 
 
Signature/Thumb print of the Subject/Legally Acceptable Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: Dr. Immanuel Subash.G 
 
Signature/Thumb print and name of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Patient data sheet: 
 
 id name h age sex marital occupa
tion 
exclusi
on 
consen
t 
diagnos
is 
hp status duratio
n 
treatm
ent 
steroids 
1 dilip 
kumar 
yadav 
205177
f 
47 1 TRUE profess
or 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
2 lakshmi 
p 
835240
f 
43 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
3 raghav
endra 
kumar 
mishra 
710372
f 
47 1 TRUE clerk FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
4 sumita 
paul 
826076
f 
39 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
5 ashok 
bagaria 
872761
f 
50 1 TRUE busines
s 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
6 abdul 
razzak 
319317
d 
52 1 TRUE driver FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
7 mahmu
da 
aktar 
979493
a 
42 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
8 jayanth
i k 
867199
f 
54 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
9 munes
hwari 
devi 
770720
f 
61 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
10 md 
zamil 
ansari 
261074
f 
43 1 TRUE teacher FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
11 erica 
baruah
n d 
860948
f 
44 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
12 lakshm
an jha 
862316
f 
44 1 TRUE clerk FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
13 aruna 467340
f 
57 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 3 TRUE TRUE 
14 basude
b 
karmak
ar 
525440
b 
46 1 TRUE clerk FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
15 chandr
a nand 
775779
f 
52 1 TRUE teacher FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
16 tapan 
dey 
949808
c 
61 1 TRUE service FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
17 samir 
ranjan 
patra 
794619
c 
52 1 TRUE teacher FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
18 ganesh 
chandr
a mitra 
758351
d 
56 1 TRUE clerk FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
19 suppat
hal 
067591
f 
67 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
20 md 
rajwan 
mia 
161932
f 
40 1 TRUE clerk FALSE TRUE TRUE TRUE 2 3 TRUE TRUE 
21 sankar 
kumar 
biswas 
208563 36 1 TRUE clerk FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
22 anil 
kumar 
sinha 
226999
f 
44 1 TRUE service FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
23 urmila 
devi 
093435
f 
50 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
24 nur 
fatima 
begum 
420208
f 
45 2 TRUE teacher FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
25 sohan 
lal jain 
264263
f 
57 1 TRUE busines
sman 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
26 fr 
antony 
thomas 
745192
f 
48 1 FALSE pastor FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
27 rachita 
banerje
e 
436416
f 
40 2 TRUE engine
er 
FALSE TRUE TRUE TRUE 2 3 TRUE TRUE 
28 beulah 
sarojini 
019665
a 
65 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
29 bijoy 
kumar 
prama
nik 
427167
f 
38 1 TRUE busines
sman 
FALSE TRUE TRUE TRUE 2 3 TRUE TRUE 
30 arun 
kundu 
809171
f 
45 1 TRUE fridge 
dealer 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
31 samrat 
deb 
400516
f 
27 1 FALSE student FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
32 nomita 
ghosh 
397414
f 
31 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
33 rajesh 
kumar 
410907
f 
43 1 TRUE scientis
t 
FALSE TRUE TRUE TRUE 2 3 TRUE TRUE 
34 shanthi 
a k 
184695
f 
53 2 TRUE nurse FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
35 barna 
das 
431966
f 
25 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
36 indra 
kumari 
607454
f 
50 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
37 indu 
devi 
297427
f 
50 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
38 milton 
amos 
682899
f 
81 1 TRUE retired 
officer 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
39 pritpal 
singh 
672097
d 
52 1 TRUE busines
sman 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
40 preeth
a 
ramesh 
054941
c 
40 2 TRUE teacher FALSE TRUE TRUE TRUE 2 3 TRUE TRUE 
41 md 
saiful 
islam 
871688
f 
41 1 TRUE laboure
r 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
42 minu 
kumari 
868877
f 
48 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
43 shanku
ntala 
patra 
256078
f 
51 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
44 samir 
kumar 
bhadra 
722165
d 
54 1 TRUE service FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
45 rajkum
ari 
653157
c 
62 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
46 kumara
swamy 
raju 
083114
f 
62 1 TRUE retired 
princip
al 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
47 ram 
kishan 
jaiswal 
488181
d 
30 1 TRUE service FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
48 asha 
devi 
302560
c 
49 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
49 sanjib 
das 
912941
f 
32 1 TRUE teacher FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
50 boaraia
h 
784651
f 
64 1 TRUE retired FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
51 subhaji
t 
manna 
912575
f 
21 1 FALSE student FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
52 koly 
begum 
869341
f 
42 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
53 shamsh
un 
nahar 
208621
f 
45 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
54 jamal 
ara 
789034
f 
48 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
55 ravindr
a 
prakas
h 
017579
g 
46 1 TRUE clerk FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
56 beni 
madha
v jha 
012748
g 
52 1 TRUE govern
ment 
service 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
57 laxmi 
devi 
262533
d 
51 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
58 mayan
k 
chaturv
edi 
020981
f 
53 1 TRUE clerk FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
59 sarava
nan 
995374
d 
43 1 TRUE engine
er 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
60 vishwa
nath 
harihar
an 
693587
f 
31 1 TRUE engine
er 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
61 rekha 
kumari 
653245
f 
47 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
62 bijay 
kumar 
152551
f 
43 1 TRUE service FALSE TRUE TRUE TRUE 2 2 TRUE TRUE 
aggarw
al 
63 gurusw
amy k 
293867
f 
47 1 TRUE bill 
collect
or 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
64 utpal 
mukhe
rjee 
602289
f 
36 1 TRUE clerk FALSE TRUE TRUE TRUE 2 2 TRUE TRUE 
65 mani 
bhusha
n 
prasad 
603072
f 
48 1 TRUE busines
sman 
FALSE TRUE TRUE TRUE 2 2 TRUE TRUE 
66 abha 
gupta 
477672
f 
40 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 2 TRUE TRUE 
67 indu 
devi 
garodia 
693755
f 
40 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
68 john t u 727928
f 
55 1 TRUE manag
er 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
69 sudhan
shu 
sekhar 
039175
d 
59 1 TRUE clerk FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
70 kiran 
devi 
agarwa
l 
259273
d 
54 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
71 manoj 
kumar 
jaiswal 
385934
f 
43 1 TRUE busines
sman 
FALSE TRUE TRUE TRUE 2 4 TRUE TRUE 
72 renu 
devi 
103820
d 
51 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
73 rikeba 
devi 
397430
f 
61 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 3 FALSE FALSE 
74 sabitha 
singh 
954543
c 
45 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 2 4 FALSE FALSE 
75 fazeela 
nausha
d 
613640
f 
34 2 TRUE house
wife 
FALSE TRUE TRUE TRUE 1 1 FALSE FALSE 
 
 
dose treatm
ent1 
other fatigue fas score skin type eye type1 liver type2 spleen type3 brain 
4 4 FALSE TRUE TRUE 22 FALSE TRUE 1 FALSE FALSE FALSE 
FALSE TRUE TRUE 23 TRUE 4 FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 19 FALSE TRUE 1 FALSE FALSE FALSE 
FALSE TRUE TRUE 27 FALSE FALSE TRUE 2 TRUE 1 FALSE 
4 4 FALSE TRUE TRUE 27 FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE TRUE 13 TRUE 4 FALSE FALSE FALSE FALSE 
2 4 FALSE TRUE TRUE 27 TRUE 1 TRUE 1 FALSE FALSE FALSE 
1 FALSE TRUE TRUE 23 FALSE FALSE FALSE FALSE FALSE 
1 FALSE TRUE TRUE 26 FALSE TRUE 1 FALSE FALSE FALSE 
FALSE TRUE TRUE 27 TRUE 2 TRUE 1 FALSE FALSE FALSE 
1 FALSE TRUE TRUE 25 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 29 FALSE TRUE 3 FALSE FALSE FALSE 
3 3 FALSE TRUE TRUE 22 FALSE FALSE TRUE 3 TRUE 1 FALSE 
FALSE TRUE TRUE 27 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE FALSE TRUE 18 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE FALSE TRUE 21 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE FALSE TRUE 18 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 23 FALSE TRUE 1 FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 26 TRUE 1 TRUE 3 FALSE TRUE 1 FALSE 
4 3 FALSE TRUE TRUE 28 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 22 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 22 FALSE TRUE 1 FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 32 FALSE FALSE FALSE FALSE FALSE 
3 4 FALSE FALSE TRUE 21 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 24 FALSE FALSE FALSE FALSE FALSE 
1 FALSE FALSE TRUE 22 FALSE FALSE FALSE FALSE FALSE 
3 3 FALSE TRUE TRUE 24 TRUE 2 TRUE 1 FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 24 FALSE TRUE 1 FALSE FALSE FALSE 
3 3 FALSE FALSE TRUE 19 FALSE FALSE TRUE 3 FALSE FALSE 
FALSE TRUE TRUE 24 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 24 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 30 FALSE FALSE FALSE FALSE TRUE 
3 3 FALSE FALSE TRUE 21 FALSE FALSE FALSE FALSE TRUE 
4 4 FALSE TRUE TRUE 25 FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE TRUE 18 TRUE 2 FALSE FALSE FALSE FALSE 
3 4 FALSE FALSE TRUE 15 FALSE TRUE 1 FALSE FALSE FALSE 
3 4 FALSE TRUE TRUE 21 FALSE TRUE 1 FALSE FALSE FALSE 
FALSE TRUE TRUE 30 TRUE 3 FALSE FALSE FALSE FALSE 
3 4 FALSE TRUE TRUE 29 FALSE FALSE FALSE FALSE FALSE 
3 3 FALSE TRUE TRUE 24 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 28 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 21 TRUE 2 FALSE TRUE 2 TRUE 1 FALSE 
4 4 FALSE TRUE TRUE 28 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 22 TRUE 2 TRUE 1 FALSE FALSE FALSE 
4 4 FALSE TRUE TRUE 27 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE FALSE TRUE 11 TRUE 2 FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 27 FALSE TRUE 1 FALSE FALSE FALSE 
FALSE FALSE TRUE 14 FALSE TRUE 3 FALSE FALSE FALSE 
FALSE TRUE TRUE 25 FALSE FALSE TRUE 1 FALSE FALSE 
FALSE TRUE TRUE 24 TRUE 2 FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 22 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 25 TRUE 2 FALSE TRUE 2 TRUE 1 TRUE 
4 4 FALSE TRUE TRUE 23 FALSE TRUE 1 FALSE FALSE FALSE 
FALSE TRUE TRUE 23 FALSE FALSE TRUE 1 FALSE FALSE 
FALSE TRUE TRUE 26 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 28 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 23 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 23 FALSE FALSE FALSE FALSE FALSE 
4 4 FALSE FALSE TRUE 21 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 25 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 27 FALSE FALSE FALSE FALSE FALSE 
3 2 FALSE TRUE TRUE 24 TRUE 2 FALSE FALSE FALSE FALSE 
FALSE FALSE TRUE 18 FALSE FALSE FALSE FALSE FALSE 
3 2 FALSE TRUE TRUE 24 FALSE FALSE FALSE FALSE FALSE 
2 2 FALSE FALSE TRUE 21 FALSE FALSE FALSE FALSE FALSE 
2 2 FALSE TRUE TRUE 31 FALSE FALSE TRUE 2 TRUE 1 FALSE 
FALSE TRUE TRUE 25 FALSE TRUE 1 FALSE FALSE FALSE 
FALSE TRUE TRUE 26 FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE TRUE 16 FALSE TRUE 1 FALSE FALSE FALSE 
4 4 FALSE FALSE TRUE 14 FALSE TRUE 1 TRUE 1 FALSE FALSE 
3 3 FALSE TRUE TRUE 26 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 18 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 24 FALSE FALSE FALSE FALSE FALSE 
FALSE TRUE TRUE 23 TRUE 4 FALSE TRUE 1 TRUE 1 FALSE 
FALSE TRUE TRUE 24 FALSE FALSE FALSE FALSE FALSE 
 
type4 gland type5 bone type6 ent type7 heart type8 bonejoi
nt 
type9 calcium
re 
type10 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE TRUE 1 
FALSE FALSE TRUE 1 FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE TRUE 1 FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE TRUE 1 FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE TRUE 1 FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE TRUE 2 FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE TRUE 1 FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE TRUE 2 
TRUE 1 FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
1 FALSE FALSE FALSE FALSE FALSE FALSE 
1 FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE TRUE 1 FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE TRUE 2 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE TRUE 1 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE TRUE 1 
FALSE FALSE FALSE FALSE FALSE FALSE 
1 FALSE FALSE FALSE FALSE TRUE 1 FALSE 
FALSE FALSE FALSE FALSE FALSE TRUE 2 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE TRUE 1 FALSE 
FALSE FALSE FALSE FALSE TRUE 1 FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE TRUE 1 FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE FALSE 
 
 
